A sarcoma originating in bone-forming cells, affecting the ends of long bones. It is the most common and most malignant of sarcomas of the bones, and occurs chiefly among 10- to 25-year-old youths. (From Stedman, 25th ed)
| Excerpt | Reference |
|---|
| "When Dunn osteosarcoma is freeze-dried and then implanted, the tumor is resorbed and replaced by deposits of normal cartilage, bone, and bone marrow." | ( Felser, JM; Finerman, GA; Hanamura, H; Miki, T; Nakata, N; Nogami, H; Urist, MR, 1977) |
| "Two cases of osteosarcoma are described arising in patients who had undergone angiography with Thorotrast during childhood." | ( Costa, J; Ketcham, AS; Sindelar, WF, 1978) |
| "Two children with osteosarcoma are presented in whom Wernicke encephalopathy with vomiting occurred during the chemotherapy." | ( Kálmánchey, R; Koós, R; Magyarossi, E; Majtényi, K, 1992) |
| "Osteosarcoma is the one of the tumors that's prognosis have been improved dramatically by the introduction of chemotherapy consisting mainly of adriamycin, high-dose methotrexate with Leucovorin rescue and cisplatinum." | ( Isii, S; Isu, K; Takeda, N; Ubayama, Y; Usui, M; Yagi, T; Yamawaki, S, 1990) |
| "Multiple osteosarcoma is a rare tumour which usually has a poor prognosis." | ( Baranzelli, MC; Bouretz, JC; Demaille, MC; Dusol, F; Gosselin, P, 1989) |
| "We conclude that osteosarcomas are not deficient in HPRT activity." | ( Houghton, JA; Houghton, PJ; Meyer, WH, 1987) |
| "The MGH-OGS murine osteosarcoma is a transplantable tumor that resembles the human disease with respect to histology, local invasiveness, metastatic characteristics, tumor ploidy, and its response to chemotherapy." | ( Bell, DF; Bell, RS; Gebhardt, MC; Mankin, HJ; Rosenberg, AE; Roth, YF; Suit, HD, 1988) |
| "Osteosarcoma is a heterogeneous tumor." | ( Chmell, MJ; Rodgers, WH; Schwartz, HS; Svitek, C; Wang, H, 1995) |
| "Extraskeletal osteosarcomas are rare malignancies that account for about 1% of all soft tissue sarcomas." | ( Fetsch, JF; Lee, BP; Lee, JS; Nascimento, AG; Pritchard, DJ; Wasdhal, DA, 1995) |
| "Extraskeletal osteosarcoma is a high grade malignant tumor associated with a 5-year survival rate of 37% (95% confidence interval, 28%-59%)." | ( Fetsch, JF; Lee, BP; Lee, JS; Nascimento, AG; Pritchard, DJ; Wasdhal, DA, 1995) |
| "Canine osteosarcoma is a highly metastatic cancer commonly seen in large breed dogs." | ( Kurzman, ID; MacEwen, EG, 1996) |
| "Osteosarcoma is a clinically heterogeneous disease which continues to resist biologic diagnosis, classification, or staging." | ( Womer, RB, 1996) |
| "Human osteosarcomas are aggressive bone tumors." | ( Heino, J; Laine, A; Riikonen, T; Vihinen, P, 1996) |
| "Treatment for osteosarcoma is problematic because there are no prognostic markers." | ( Bidwell, J; Feister, H; Fey, E; Hock, J; Holden, J; McCabe, R; Onyia, J; Rougraff, B, 1997) |
| "Extraskeletal osteosarcomas are rare tumors, and the telangiectatic variety is the least common histological variety in this group." | ( Connell, D; Dubec, JJ; Janzen, D; Lee, MJ; Logan, PM; Masri, B; Munk, PL; O'Connell, JX, 1997) |
| "Osteosarcoma is a common primary bone malignancy most often involving the long bones and occurring in the second decade of life." | ( Epley, KD; Karesh, JW; Lasky, JB, 1998) |
| "Canine and human osteosarcoma are very similar with respect to clinical presentation, radiological and histopathological features, metastatic rate and pattern and response to therapy." | ( Barhoumi, R; Kochevar, DT; Mealey, KL; Rogers, K, 1998) |
| "Different types of osteosarcoma are described, each of them with a definite clinical and radiographic pattern." | ( Montanari, N; Romagnoli, R; Spina, V, 1998) |
| "Osteosarcomas are malignant tumours producing osteoid and/or bone." | ( Endo, N; Hatano, H; Hayami, T; Hotta, T; Ogose, A; Takahashi, HE; Tokunaga, K; Yamagiwa, H, 1998) |
| "Multifocal osteosarcoma is uncommon." | ( Abramovici, L; Kenan, S; Rosenberg, Z; Steiner, GC, 1998) |
| "Osteosarcoma is a common malignant tumor." | ( Akamatsu, N; Hamada, Y; Seki, K; Shiiki, K; Tasaka, K; Yoshikawa, H, 2000) |
| "Osteosarcoma is one of the most common primary malignant tumors of bone." | ( Debatin, KM; Ewerbeck, V; Fellenberg, J; Mau, H; Nedel, S, 2000) |
| "Osteosarcoma is the most frequent highly malignant bone-tumor with a peak manifestation during the second and third decade of life." | ( Kotz, R; Trieb, K, 2001) |
| "Primary pulmonary osteosarcoma is an extremely rare malignancy." | ( Chapman, AD; Cockburn, JS; Hutcheon, AW; Kerr, KM; McLeod, HL; Nicolson, MC; Pritchard, SC; Rooney, PH; Yap, WW, 2001) |
| "The incidence of osteosarcoma is increased 500-fold in patients who inherit mutations in the RB gene." | ( Carty, SA; Forrester, WC; Hinds, PW; Lee, JS; Piscopo, DM; Thomas, DM; Wang, WF, 2001) |
| "Osteosarcoma is a primary malignancy of bone." | ( Berend, KR; Dibernardo, L; Harrelson, JM; Moore, JO; Pietrobon, R; Scully, SP, 2001) |
| "Osteosarcoma is a malignant tumor with heterogeneous features both in histological and biological aspects." | ( Aoyama, T; Hosaka, T; Murakami, H; Nakamata, T; Nakamura, T; Nakayama, T; Nishijo, K; Okamoto, T; Toguchida, J; Tsuboyama, T, 2002) |
| "Osteosarcoma is an aggressive primary bone cancer characterized by expression of platelet-derived growth factor (PDGF) and its cognate receptor." | ( Bar-Eli, M; Doucet, M; Fidler, IJ; Lev, DC; Lewis, V; McGary, EC; Mills, L; Weber, K, 2002) |
| "Skeletal osteosarcoma is the most common primary malignant neoplasm of the bone, predominantly occurring in the metaphysis of the long bones of adolescents and young adults." | ( Covello, SP; Humphreys, TR; Lee, JB, 2003) |
| "Extraskeletal osteosarcoma is a rare malignant soft tissue tumor." | ( Buza, N; Horváth, V; Kocsis, J; Oláh, A; Olgyai, G, 2003) |
| "Recurrent osteosarcoma is a drug-resistant disease with a dismal prognosis." | ( Bagatell, R; Demetri, GD; Goorin, AM; Gorlick, R; Guzman, C; Harmon, D; Healey, JH; Huvos, AG; Jimeno, J; Kolb, EA; Laverdiere, C; Maki, RG; Meyers, PA; Ruiz-Casado, A; Supko, JG; Wexler, L, 2003) |
| "Osteosarcoma is the most frequent primary high grade bone tumor, usually occurring in adolescents and children." | ( Bacci, G; Fasano, MC; Ferrari, S; Pratelli, L; Zolezzi, C, 2003) |
| "Osteosarcoma is the most common malignant bone tumor of childhood." | ( Cheng, YY; Huang, L; Kumta, SM; Lee, KM; Li, K, 2004) |
| "Extraskeletal osteosarcoma is a rare malignancy, which accounts for 1-2% of all soft tissue sarcomas; occurrence of these tumors in the head and neck is extremely rare." | ( Hasegawa, S; Hatano, H; Ito, T; Kobayashi, H; Morita, T; Segawa, H, 2005) |
| "Osteosarcomas are common primary malignant bone tumors that do not respond to conventional low-dose treatments of methotrexate (Mtx), suggesting an intrinsic resistance to this drug." | ( Flintoff, WF; Gorlick, R; Sadlish, H; Williams, FM; Yang, R, 2004) |
| "High-grade osteosarcoma is an extremely aggressive neoplasm, where over 80% of patients present with life-threatening micrometastases at diagnosis." | ( Baldini, N; Baroetto Parisi, R; Buracco, P; Cagliero, E; Comandone, A; Ferracini, R; Manara, MC; Morello, E; Scotlandi, K, 2004) |
| "Osteosarcoma is the most common primary malignant tumor of bone (annual incidence: 2 - 3/Mio)." | ( Bielack, S; Flege, S, 2004) |
| "Osteosarcoma is the most common solid tumour of childhood." | ( Grimer, RJ, 2005) |
| "Osteosarcoma is the most common malignant bone tumor in children." | ( Antonescu, CR; Berens, ME; Brown, KM; Chen, W; Daluski, A; Gorlick, R; Healey, JH; Henry, MM; Hilmer, SC; Huvos, AG; Lafleur, B; Macdonald, TJ; Mazza, B; McDonough, WS; Meyers, PA; Mintz, MB; Ramsey, KE; Sowers, R; Stephan, DA, 2005) |
| "Osteosarcoma is the most frequent primary malignant tumor of bone with a high propensity for metastasis." | ( Helman, LJ; Khanna, C; Mendoza, A; Wan, X, 2005) |
| "Extraskeletal osteosarcoma is an extremely rare high-grade malignant soft tissue tumor, which accounts for approximately 4% of osteosarcomas and less than 1% of all soft tissue sarcomas." | ( Kajihara, M; Kidani, T; Miki, H; Mochizuki, T; Sakayama, K; Sugawara, Y, 2005) |
| "Extraskeletal osteosarcoma is a rare malignant soft-tissue tumor." | ( Hirata, M; Kajihara, M; Kidani, T; Kikuchi, K; Miki, H; Miyazaki, T; Mochizuki, T; Sakayama, K; Sugawara, Y, 2005) |
| "Osteosarcoma is extremely rare in the hand and forearm." | ( Bernd, L; Bielack, S; Daecke, W; Ewerbeck, V; Jürgens, H; Kabisch, H; Kevric, M; Kotz, R; Martini, AK; Winkelmann, W, 2005) |
| "Osteosarcoma is a very malignant bone tumor which has a high metastatic potential and usually lead to poor prognosis." | ( Chiang, HS; Huang, TF; Tang, CH; Yang, RS; Yeh, CS, 2005) |
| "Osteosarcoma is the most common malignant bone tumor in children." | ( Chintagumpala, M; Davino, N; Helman, L; Hicks, J; Johnson, M; Lau, CC; Man, TK; Meyer, W; Murray, J; Perlaky, L; Shen, J; Triche, T; Visvanathan, J; Wong, KK, 2005) |
| "Osteosarcoma is the most common primary bone tumour in young adults." | ( Auberger, P; Bouvet, S; Fromigué, O; Haÿ, E; Jacquel, A; Marie, PJ; Modrowski, D, 2006) |
| "Osteosarcoma is a rare malignancy of largely unknown etiology." | ( Douglass, CW; Fears, TR; Hoover, RN; Medina, N; Whitford, GM, 2006) |
| "Osteosarcoma is the most common primary bone tumor and most frequently develops during adolescence." | ( Maran, A; Shogren, KL; Turner, RT; Yaszemski, MJ, 2007) |
| "Osteosarcoma is an aggressive tumor found in children and young adults, originating primarily in the legs or arms." | ( Coats, H; Matthews, E; Snell, K, 2006) |
| "Since osteosarcoma is a drug-resistant disease, the aim of the present study was to explore the possible interest of therapeutic approaches including nitrogen-containing biphosphonate zoledronic acid using osteosarcoma cell lines with different genetic backgrounds." | ( Benassi, MS; Chiechi, A; Ferrari, S; Gamberi, G; Manara, MC; Pazzaglia, L; Perego, P; Picci, P; Ponticelli, F; Zanella, L, 2007) |
| "Osteosarcoma is one of the most common primary malignant tumors of the bone in children and adolescents." | ( Iguchi, T; Ikeda, Y; Kizaki, M; Miyakawa, Y; Nakabayashi, C; Nakanishi, M; Saito, K; Saya, H, 2007) |
| "Osteosarcoma is the most frequent type of primary bone cancer in children and adolescents." | ( Chung, LW; Siegal, GP; Yuan, K; Zayzafoon, M, 2007) |
| "Osteosarcoma is the most frequent primary bone tumor that develops mainly in the young, the median age of diagnosis being 18 years." | ( Battaglia, S; Blanchard, F; Gouin, F; Heymann, D; Lamoureux, F; Pilet, P; Pitard, B; Redini, F; Richard, P; Trichet, V; Wittrant, Y, 2007) |
| "Osteosarcoma is the most common primary malignant bone tumor in childhood and adolescence." | ( Dudas, J; Harisi, R; Jeney, A; Nagy-Olah, J; Szendroi, M; Timar, F, 2007) |
| "Osteosarcoma is the most common primary bone tumor, but the pathogenesis is not well understood." | ( Choe, M; Choi, EM; Ha, KS; Han, JA; Kim, H; Kim, JI; Kim, SR; Kim, SS; Kim, YM; Lee, EJ; Park, JH, 2007) |
| "Osteosarcoma is a rare tumor in elderly patients." | ( Jeon, DG; Kim, MS; Lee, SY; Sim, YS, 2007) |
| "Osteosarcoma is the most common primary bone tumour associated with childhood and adolescence." | ( Berdiaki, A; Karamanos, NK; Katonis, P; Nikitovic, D; Tsatsakis, A; Tzanakakis, GN; Zafiropoulos, A, 2008) |
| "Osteosarcoma is the most frequent primitive malignant tumor of the skeletal system, characterized by an extremely aggressive clinical course that still lacks an effective treatment." | ( Angelucci, A; Bernardini, G; Bologna, M; Botta, M; Collodel, G; Di Stefano, A; Magrini, D; Manetti, F; Orlandini, M; Santucci, A; Schenone, S; Serchi, T; Spreafico, A; Tintori, C, 2008) |
| "Osteosarcoma is a rare malignancy, and patients with this disease benefit from adjuvant chemotherapy." | ( Atalar, AC; Basaran, M; Bavbek, ES; Bilgic, B; Eralp, L; Onat, H; Ozger, H; Saglam, S; Sakar, B, 2007) |
| "Osteosarcoma is the most common primary bone tumor in children and young adults." | ( Fromigué, O; Hamidouche, Z; Marie, PJ, 2008) |
| "Osteosarcomas are highly malignant tumours of bone, and are rare in the craniofacial area." | ( Bacon, C; Egerer, G; Freier, K; Hofele, CM; Thiele, OC, 2008) |
| "Low grade central osteosarcoma is a rare primary bone tumor." | ( Khan, SA; Kumar, A; Rastogi, S; Safaya, R; Varshney, MK, 2008) |
| "Osteosarcomas are heterogeneous bone tumors whose common characteristic is the production of an abundant nonmineralized (ECM)-osteoid." | ( Berdiaki, K; Chalkiadaki, G; Karamanos, N; Nikitovic, D; Tzanakakis, G, 2008) |
| "Osteosarcoma is characterized by a high malignant and metastatic potential, which points to the need for new therapeutic strategies to prevent cell metastasis." | ( Fromigué, O; Hamidouche, Z; Marie, PJ, 2008) |
| "Osteosarcoma is the most common primary bone tumor associated with childhood and adolescence." | ( Chang, CS; Chen, JT; Fong, YC; Hsu, CW; Li, TM; Liu, JF; Tang, CH, 2008) |
| "Osteosarcoma is one of the most common pediatric cancers." | ( Arvanitis, C; Bendapudi, PK; Felsher, DW; Gambhir, SS; Tseng, JR, 2008) |
| "Osteosarcoma is a ubiquitous and highly aggressive malignant bone tumor." | ( Chen, P; Dong, Y; Lin, F; Shen, Z; Sun, YJ; Tang, LN; Yao, Y; Zhao, H; Zheng, SE, 2009) |
| "Osteosarcoma is the most common second neoplasm in patients with retinoblastoma." | ( George, T; Juneja, M; Mahajan, S, 2008) |
| "Osteosarcoma is the most frequent primary bone malignant tumor that develops mainly in children and adolescents." | ( Baud'huin, M; Garrigue-Antar, L; Heymann, D; Lamoureux, F; Miot-Noirault, E; Picarda, G; Pitard, B; Rédini, F; Trichet, V; Vidal, A, 2009) |
| "Osteosarcoma is highly resistant to current chemotherapy regimens." | ( Freeman, J; Gazitt, Y; Kolaparthi, V; Moncada, K; Thomas, C, 2009) |
| "Osteosarcoma is the most common malignant primary bone tumor in childhood." | ( Gorlick, R; O'Day, K, 2009) |
| "Osteosarcoma is a rare malignant bone tumor most commonly occurring in children and young adults presenting with painful swelling." | ( Kharb, S; Kundu, ZS; Lal, H; Sandhu, R, 2011) |
| "Osteosarcoma is the most common non-hematologic primary cancer type that develops in bone." | ( Altieri, S; Bortolussi, S; Bruschi, P; Cansolino, L; Clerici, AM; Dionigi, P; Ferrari, C; Gaspari, A; Stella, S; Zonta, A; Zonta, C, 2009) |
| "Osteosarcoma is a highly malignant bone tumor and is the most commonly encountered malignant bone tumor in children and adolescents." | ( Jung, ST; Kim, YK; Xin, ZF, 2009) |
| "Osteosarcoma is the most prevalent bone tumor in children and adolescents." | ( De Las Rivas, J; Folio, C; Lecanda, F; Patiño-García, A; San Julián, M; Sierrasesúmaga, L; Toledo, G; Zalacain, M; Zandueta, C, 2009) |
| "Osteosarcomas are the most prevalent primary bone tumors found in pediatric patients." | ( Aung, KZ; Cool, SM; Galindo, M; Gupta, A; Leong, DT; Ling, L; Nathan, SS; Pereira, BP; Pho, RW; Salto-Tellez, M; Stein, GS; van Wijnen, AJ; Zhou, Y, 2009) |
| "Osteosarcoma is the most common skeletal malignancy in the dog and in young humans." | ( Anderson, PM; Cannan, VA; Crabbs, TA; Gordon, N; Kleinerman, E; Koshkina, N; Rodriguez, CO; Skorupski, KA; Wilson, DW, 2010) |
| "Osteosarcomas are primary bone tumors of osteoblastic origin that mostly affect adolescent patients." | ( Benavidez, D; Eliseev, RA; Shapovalov, Y; Zuch, D, 2010) |
| "Osteosarcoma is one of the most common malignant cancers afflicting young adults." | ( Dan, L; Guo, H; Leung, W; Quan, X; Tian, Z; Xu, C, 2009) |
| "Osteosarcoma is a bone tumor that frequently develops during adolescence." | ( Benedikt, MB; Mahlum, EW; Maran, A; Shogren, KL; Spelsberg, TC; Subramaniam, M; Yaszemski, MJ, 2010) |
| "Osteosarcoma is an aggressive tumor of mesenchymal origin, capable of producing osteoid and immature bone." | ( Eftekhari, F, 2009) |
| "Osteosarcoma is the most common primary malignancy of bone." | ( Bi, Y; Chen, L; Deng, ZL; Haydon, RC; He, BC; He, CJ; He, TC; Hu, Y; Huang, J; Jiang, W; Kim, SH; Lei, X; Liu, B; Luo, J; Luo, Q; Luo, X; Luu, HH; Rastegar, F; Shen, J; Shi, Q; Wagner, ER; Wang, Y; Zhang, BQ; Zhang, W; Zhou, Q; Zuo, GW, 2010) |
| "Osteosarcoma is extremely rare in preschool children." | ( Bielack, S; Bodmer, N; Dominkus, M; Gadner, H; Jundt, G; Jürgens, H; Kager, L; Klingebiel, T; Lang, S; Zoubek, A, 2010) |
| "Osteosarcoma is the most frequent malignant bone tumor with a peak incidence in the second and third decades of life." | ( Gan, M; Mao, N; Shi, Q; Yang, H; Zhu, X; Zou, J, 2010) |
| "Osteosarcoma is a primary malignant bone tumor, whose peak incidence occurs in the second decade of life during the adolescent growth spurt." | ( Ambroszkiewicz, J; Chełchowska, M; Gajewska, J; Klepacka, T; Laskowska-Klita, T; Woźniak, W, 2010) |
| "Osteosarcoma is a common primary malignant tumor of bone with a poor prognosis due to its propensity for metastasis." | ( Li, XH; Wang, WB; Yang, GF; Zhao, Z, 2010) |
| "Osteosarcoma is the most common primary bone tumour in children usually treated with chemotherapy and surgery." | ( Baum, RP; Howman-Giles, R; Schmidt, M; Simon, T, 2010) |
| "Osteosarcoma is the first primary malignant bone tumor, characterized by a complex genetic and resistance to conventional treatments." | ( Alberti, L; Besse, A; Blay, JY; Duc, A; Dutour, A; Gougelet, A; Perez, J; Pissaloux, D, 2011) |
| "Osteosarcoma is the most frequent secondary malignancy following radiotherapy of patients with bilateral retinoblastoma." | ( Atkinson, MJ; Domke, T; Esposito, I; Gonzalez-Vasconcellos, I; Kuosaite, V; Nathrath, M; Rosemann, M; Sanli-Bonazzi, B, 2011) |
| "Osteosarcoma is the most common primary malignancy of bone with poorly characterized molecular pathways important in its pathogenesis." | ( Bi, Y; Chen, L; Gao, JL; Gao, Y; Haydon, RC; He, BC; He, TC; Hu, N; Huang, E; Jiang, W; Kim, SH; Li, M; Liu, X; Luo, J; Luo, Q; Luo, X; Luther, G; Luu, HH; Rastegar, F; Shen, J; Shenaq, D; Shi, Q; Wagner, ER; Wang, L; Yang, K; Zuo, GW, 2010) |
| "Osteosarcoma is a primary bone cancer which occurs mainly in children." | ( Kim, SH; Lee, SJ; Lee, YS; Park, JH; Sihn, CR, 2011) |
| "Osteosarcoma is the most common primary tumor of bone." | ( Barbry, P; Fromigue, O; Hamidouche, Z; Lecanda, F; Mari, B; Marie, PJ; Patino, A; Vaudin, P, 2011) |
| "Osteosarcoma is the most common type of malignant bone cancer, accounting for 35% of primary bone malignancies." | ( Arrabal, PM; Cifuentes, M; Domínguez, D; García, MA; Jara, N; Martínez, F; Medina, RA; Nualart, F; Weil, B; Yañez, MJ, 2011) |
| "Osteosarcoma is the most common primary malignant bone tumor, occurring mainly in children and adolescents, and survival largely depends on their response to chemotherapy." | ( Chiu, HW; Ho, SY; Lin, W; Wang, YJ, 2011) |
| "Osteosarcoma is the most common type of primary bone cancer in children and adolescents." | ( Choy, E; Duan, Z; Harmon, D; Hornicek, FJ; Liu, X; Mankin, H; Yang, C; Yang, S, 2011) |
| "Osteosarcoma is a malignant tumor commonly found in human and animals." | ( Chou, FI; Hsu, CF; Liao, JW; Lin, SY; Lin, YC; Peir, JJ, 2011) |
| "Although rare, osteosarcoma is an aggressive cancer that often metastasizes to the lungs." | ( Altiok, S; Bui, MM; Chu, B; Fu, W; Gemmer, J; Ma, L; Pledger, WJ; Wang, X, 2011) |
| "Osteosarcoma is the most common malignant primary bone tumor in children and adolescents and is characterized by a high metastatic potential." | ( Borrelli, V; Chiosi, E; D'Auria, R; Di Gesto, D; Forni, M; Illiano, F; Illiano, G; Naviglio, S; Sorrentino, A; Spina, A, 2011) |
| "Osteosarcoma is the most common primary malignant bone cancer in children and adolescents." | ( Liang, Y; Shen, JN; Tang, QL; Wang, J; Xie, XB; Yin, JQ; Zhao, ZQ; Zou, CY, 2011) |
| "Osteosarcomas are the most common solid malignant bone tumors, but little is known of their origin." | ( Gowda, AL; Lucas, PA; Miran, S; Russinoff, S, 2011) |
| "This indicates osteosarcomas are composed, at least in part, of primitive stem cells capable of differentiating into tissues from all three dermal lineages." | ( Gowda, AL; Lucas, PA; Miran, S; Russinoff, S, 2011) |
| "Osteosarcoma is the most frequent malignant primary bone tumor that occurs mainly in the young, with an incidence peak observed at age 18 years." | ( Brion, R; Ebetion, FH; Heymann, D; Moriceau, G; Redini, F; Roelofs, AJ; Rogers, MJ, 2012) |
| "Osteosarcoma is the most common primary malignant tumor of bone, which frequently occurs in the second decade of life." | ( Brassesco, MS; Montaldi, AP; Morales, AG; Oliveira, JC; Pezuk, JA; Sakamoto-Hojo, ET; Scrideli, CA; Tone, LG, 2011) |
| "Osteosarcoma is the most common primary bone tumor in children and adolescents and is typically associated with a poor prognosis." | ( Kang, T; Li, JC; Liang, Y; Shen, JN; Tang, QL; Wang, J; Xie, XB; Yin, JQ; Zeng, YX; Zhao, ZQ; Zou, CY, 2011) |
| "Osteosarcoma is the most common malignant bone tumor in children and young people." | ( Kallis, C; Strauss, SJ; Whelan, JS; Windsor, RE; Wood, NE, 2012) |
| "Osteosarcoma is a type of cancer which is difficult to treat and the purpose of this study was to investigate the effects of bufalin on the migration and invasion of human osteosarcoma U-2 OS cells." | ( Chen, YY; Chueh, FS; Chung, JG; Ho, HC; Huang, AC; Kuo, CL; Liao, CL; Yang, JS, 2014) |
| "Osteosarcoma is an aggressive malignancy of the bone and an increase in serum alkaline phosphatase concentration has clinical prognostic value in both humans and canines." | ( Huelsmeyer, MK; Muthuswamy, A; Piskun, CM; Stein, TJ; Thompson, V, 2011) |
| "Osteosarcoma is a bone cancer that affects many children and young adults." | ( Dang, TA; Li, Y; Man, TK, 2012) |
| "Osteosarcoma is a devastating tumor of bone, primarily affecting adolescents." | ( Eliseev, RA; Giang, AH; O'Keefe, R; Rosier, R; Schwarz, E; Shapovalov, Y; Zuch, D, 2012) |
| "Osteosarcoma is a high grade aggressive neoplasm with poor survival." | ( Alves, MT; Burnier, MN; de Toledo, SR; Di Cesare, S; Garcia, RJ; Miiji, LN; Odashiro, AN; Petrilli, AS, 2011) |
| "Osteosarcoma is the most common primary malignancy of the bone." | ( Li, J; Li, X; Peng, C; Si, H; Wang, X; Zhai, L, 2012) |
| "Osteosarcoma is the most common primary malignant tumour in young adults." | ( Boecker, U; Bui-Nguyen, B; Duffaud, F; Egerer, G; Ferrari, S; Rassam, H, 2012) |
| "Canine osteosarcoma is an insidious disease with few effective treatment modalities; therefore, use of pharmacologic intervention to improve mortality or morbidity is constantly sought." | ( Bushey, JJ; Goupil, RC; Peters-Kennedy, J; Wakshlag, JJ, 2012) |
| "Osteosarcoma is one of the most common primary malignant bone tumors in children and adolescents." | ( Imano, M; Itoh, T; Nishida, S; Ogaki, M; Satou, T; Tsubaki, M; Yanae, M, 2012) |
| "Osteosarcoma is a malignant tumor with high ability to form invasion and metastasis." | ( Han, J; Luo, C; Peng, T; Shen, J; Tan, P; Yong, B, 2012) |
| "Osteosarcoma is the most frequently diagnosed primary bone tumor in dog." | ( Krajarng, A; Nilwarankoon, S; Suksamrarn, S; Watanapokasin, R, 2012) |
| "Osteosarcoma is a bone tumor that often affects children and young adults." | ( Goyal, R; Maran, A; Riester, SM; Shogren, KL; Wimbauer, F; Yang, C; Yaszemski, MJ; Zhang, M, 2012) |
| "Osteosarcoma is the most common primary bone malignancy with a notorious feature of high metastasis." | ( Chen, H; Lin, JH; Wang, FS; Wu, ZY, 2011) |
| "Osteosarcoma is the most common primary bone tumor in children and adolescents, with a 5-year disease free survival rate of 70%." | ( Borges, JP; Dias, SJ; Ferreira, IM; Novo, CM; Soares, PI, 2012) |
| "Osteosarcoma is the most common malignant primary bone tumor in children and adolescents." | ( Chiosi, E; D'Auria, R; Di Gesto, D; Di Maiolo, F; Esposito, A; Naviglio, S; Sorvillo, L; Spina, A, 2013) |
| "Osteosarcoma is a common malignant bone tumor." | ( Li, Y; Liu, C; Wang, K; Zhuang, Y, 2012) |
| "Osteosarcoma is a malignant bone tumor which is found most commonly in adolescents and young adults." | ( Feng, DP; Gong, WH; Huang, T; Jiang, GJ; Li, XC; Li, XH; Zou, CP, 2012) |
| "Osteosarcoma is the most common primary malignant tumor of bone." | ( Choy, E; Duan, Z; Hornicek, FJ; Liu, X; Mankin, H; Yang, W, 2013) |
| "Osteosarcoma is one of the most common malignant bone tumors in children and adolescents." | ( Bao, M; Cao, Z; Fu, S; Han, H; Pan, Y; Yang, B; Yang, P; Yu, D; Zhang, G; Zhou, Q, 2012) |
| "Osteosarcoma is the most common bone tumor in dogs." | ( Balko, JA; Brown, DC; Fernandez, S; Goldschmidt, MH; Holmes, ES; Kruse, MA, 2013) |
| "The treatment for osteosarcoma is a formidable challenge." | ( Dai, X; He, XJ; Jha, RK; Ma, W, 2013) |
| "Osteosarcoma is a high-grade malignant bone tumor." | ( Cao, X; Feng, D; Li, X; Liu, Y; Luo, Z; Lv, C; Wang, L; Wu, Y; Yang, M, 2013) |
| "Osteosarcoma is the most common primary bone malignancy in children and adolescents, and its clinical outcome is poor." | ( Bao, CF; Li, XH; Yang, LM, 2012) |
| "Osteosarcoma is a bone tumor that affects children and young adults." | ( Buenz, CM; Dadsetan, M; Lu, L; Maran, A; Shogren, KL; Yaszemski, MJ, 2013) |
| "Osteosarcoma is the most frequent primary malignancy of bone, and usually metastasizes to the lung and bones, while other sites are rare." | ( Amoui, M; Assadi, M; Pirayesh, E; Poor, AS; Rakhsha, A; Rakhshan, A, 2013) |
| "Osteosarcoma is an aggressive malignancy and represents the most frequent primary bone malignancy of dogs and humans." | ( Fan, TM; Holmes, KE; Huelsmeyer, MK; Kohnken, RA; Piskun, CM; Stein, TJ; Thompson, V, 2015) |
| "Osteosarcoma is the most common bone cancer in children and adolescents with a 5-year survival rate of about 70%." | ( Banerjee, S; Mackenzie, TN; Saluja, AK; Sangwan, V; Subramanian, S; Thayanithy, V, 2013) |
| "Osteosarcoma is the most common primary malignant bone tumor in children and young adults." | ( Bravo, D; Goyal, R; Maran, A; Shogren, KL; Yang, C; Yaszemski, MJ, 2013) |
| "Osteosarcoma is the most common malignant bone tumor in children and young adults." | ( Berndt, K; Born, W; Campanile, C; Fuchs, B; Muff, R; Strehler, E, 2013) |
| "Osteosarcoma is the most common primary bone tumor in childhood and adolescence." | ( Charoenkwan, P; Choeyprasert, W; Natesirinilkul, R; Sittipreechacharn, S, 2013) |
| "High-grade osteosarcoma is an aggressive tumor most often developing in the long bones of adolescents, with a second peak in the 5th decade of life." | ( Briaire-de Bruijn, IH; Cleton-Jansen, AM; Hassan, AB; Hogendoorn, PC; Kuijjer, ML; Meza-Zepeda, LA; Myklebost, O; Peterse, EF; Serra, M; van den Akker, BE, 2013) |
| "Osteosarcoma is the most common primary solid malignant bone tumor." | ( Akisue, T; Fukase, N; Hara, H; Harada, R; Kawamoto, T; Kuroda, R; Kurosaka, M; Minoda, M; Miwa, M; Onishi, Y; Sakai, Y; Toda, M; Ueha, T, 2013) |
| "Osteosarcoma is one of the most malignant tumors of childhood and adolescence that is often resistant to standard chemo- and radio-therapy." | ( Antoniewicz, J; Campanella, C; Cappello, F; Daca, A; Gorska, M; Knap, N; Kuban-Jankowska, A; Marino Gammazza, A; Popowska, U; Sielicka, A; Wakabayashi, T; Wasiewicz, T; Wozniak, M; Zmijewski, MA, 2013) |
| "Osteosarcoma is the most common primary bone tumor in children and adolescents." | ( Horne, DA; Jove, R; Liu, L; Nam, S; Tian, Y; Yang, F; Zhao, R, 2013) |
| "Osteosarcoma is the most common malignant bone tumor in children and adolescents." | ( Cho, HS; Cho, WH; Choi, YJ; Kim, HS; Lee, HJ; Oh, JH, 2013) |
| "Osteosarcoma is the most common primary tumor of bone occurring in children and adolescents." | ( Fromigué, O; Girault, I; Habel, N; Hamidouche, Z; Lecanda, F; Marie, PJ; Patiño-García, A, 2013) |
| "Osteosarcoma is a highly malignant bone tumor in children and adolescents." | ( Berger, M; Carranza, A; Coveñas, R; Gonzalez-Ortega, A; Muñoz, M; Rosso, M, 2014) |
| "Osteosarcoma is the 3rd most common human cancer in childhood and young adults, and is the leading cause of mortality." | ( Fu, Q; Lu, J; Mei, Q; Shi, L; Xu, H; Zhao, J, 2014) |
| "Osteosarcoma is a type of malignant bone tumor with high metastasis and poor prognosis." | ( Ji, QY; Meng, LJ; Wang, H; Wang, Y; Xing, FJ; Yang, ST; Zhang, HS; Zhang, HY; Zhao, JW, 2014) |
| "Osteosarcoma is a primary bone malignancy with aggressive metastatic potential and poor prognosis rates." | ( Bahety, P; Boon, CP; Ee, PL; Lee, CY; Leow, PC; Tan, KL; Yang, T, 2014) |
| "Osteosarcoma is the most frequent primary malignant bone tumor, notorious for its lung metastasis." | ( Cai, Z; Deng, B; Fu, Z; Hua, Y; Liao, Y; Shan, L; Wang, Z; Yin, F; Zeng, H; Zuo, D, 2013) |
| "Osteosarcoma is the most common form of primary malignant bone tumor that mainly occurs in juvenile patients." | ( Cao, Z; Chen, J; Ding, Y; Hu, Y; Ren, P; Wang, Y; Zhang, Y, 2014) |
| "Osteosarcoma is a rare but aggressive bone neoplasm in humans, which is commonly treated with surgery, classical chemotherapy and radiation." | ( Burger, S; Gallè, B; Mair, G; Miller, I; Steinborn, R; Walter, I; Wolfesberger, B, 2014) |
| "Osteosarcoma is a recalcitrant bone malignancy with poor responsiveness to treatments; therefore, new chemotherapeutic compounds are needed." | ( Costa, M; Ferreira de Oliveira, JM; Oliveira, H; Pinho, F; Pinho, S; Pinto, P; Remédios, C; Santos, C, 2014) |
| "Osteosarcoma is the most common primary bone tumour of both children and dogs." | ( Argyle, DJ; Gatenby, EL; Hupp, TR; Kamida, A; Pang, LY; Whitelaw, BA, 2014) |
| "Osteosarcoma is the most common primary malignant tumor of bone and accounts for around 50% of all primary skeletal malignancies." | ( Ando, T; Cates, JM; Cole, HA; Haro, H; Ohba, T; Schoenecker, JG; Schwartz, HS; Slosky, DA, 2014) |
| "High-grade osteosarcoma is a primary malignant bone tumor mostly occurring in adolescents and young adults, with a second peak at middle age." | ( Buddingh, EP; Bürger, H; Cleton-Jansen, AM; Hilhorst, R; Hogendoorn, PC; Kuijjer, ML; Mommersteeg, M; Serra, M; van den Akker, BE, 2014) |
| "Osteosarcoma is the most common primary malignant tumor, and its treatments require more effective therapeutic approaches." | ( Huang, CY; Su, HL; Tang, CH; Tsai, HC, 2014) |
| "Osteosarcoma is the most common primary malignant bone tumour characterized by osteoid production and/or osteolytic lesions of bone." | ( Blanchard, F; Brion, R; Charrier, C; Gobin, B; Heymann, D; Moriceau, G; Ory, B; Redini, F, 2014) |
| "Osteosarcoma is a common malignant bone tumor which threatens the life of young people worldwide." | ( Guan, J; Lai, X; Leung, AW; Wang, X; Xu, C; Zhang, H, 2014) |
| "Osteosarcoma is the most common type of primary malignant bone tumor in children and adolescents." | ( Meng, C; Yi, F; Yuan, H; Zhao, D; Zhu, Q, 2014) |
| "Osteosarcoma is the most common primary malignancy of bone and is characterized by a high malignant and metastatic potential." | ( Hou, CH; Hou, SM; Lin, FL; Liu, JF; Tong, KB, 2014) |
| "Osteosarcoma is the most common malignant bone tumor in children and adolescents." | ( Alonso, MM; Fueyo, J; Gomez-Manzano, C; Jauregui, P; Julián, MS; Lecanda, F; Marrodan, L; Martinez-Velez, N; Patiño-García, A; Sierrasesúmaga, L; Toledo, G; Torre, W; Urquiza, L; Vera, B; Xipell, E; Zalacain, M; Zandueta, C, 2014) |
| "Osteosarcoma is the most common primary bone cancer in children and adolescents." | ( Baldini, N; Pancotti, F; Roncuzzi, L, 2014) |
| "Osteosarcomas are the most common solid malignancies of bone." | ( Aksoy, S; Ozdemir, N; Seker, A; Seker, MM; Uncu, D; Zengin, N, 2014) |
| "Osteosarcomas are the most common primary malignant tumors of bone, showing complex chromosomal rearrangements with multiple gains and losses." | ( Barøy, T; Castro, R; Kresse, SH; Lauvrak, S; Llombart-Bosch, A; Meza-Zepeda, LA; Myklebost, O; Skårn, M; Stabell, M, 2014) |
| "Like the human, osteosarcoma is the most common bone malignancy of the dog and death from pulmonary metastasis is the most common outcome." | ( Rodriguez, CO, 2014) |
| "Osteosarcoma is a cancer characterized by formation of bone by malignant cells." | ( Anderson, PM; Rohren, E; Subbiah, V, 2014) |
| "Osteosarcoma is the most common primary bone malignancy that occurs mostly in adolescents." | ( Dolžan, V; Goričar, K; Jazbec, J; Kovač, V; Lamovec, J; Zakotnik, B, 2014) |
| "Osteosarcoma is a common primary bone tumor in children and adolescents." | ( Jiao, Y; Ju, Y; Li, W; Liu, Y; Wang, S; Wang, Y; Zhang, B; Zhang, J; Zhang, M; Zhao, L; Zhao, M; Zhao, Y, 2014) |
| "Osteosarcoma is the main malignant primary bone tumor in children and adolescents for whom the prognosis remains poor, especially when metastasis is present at diagnosis." | ( Amiaud, J; Bougras, G; Chesneau, J; Heymann, D; Heymann, MF; Lamora, A; Le Deley, MC; Leduc, M; Redini, F; Stresing, V; Talbot, J; Taurelle, J; Verrecchia, F, 2014) |
| "Human osteosarcoma is an aggressive tumor which frequently resists chemotherapy; therefore, the search for new agents for its treatment is of great importance." | ( Di, W; Feng, L; Khan, M; Ma, T; Rasul, A; Sui, Y; Sun, M; Yang, L; Zhong, L; Zhu, Q, 2014) |
| "Osteosarcoma is the most common primary malignant bone tumor in children and adolescents." | ( Liu, H; Meng, Q; Xu, X; Zhang, W; Zhao, J; Zheng, M; Zhou, G, 2014) |
| "Osteosarcoma is the most common primary malignant bone tumor in children and adolescents and is characterized by frequent metastasis and resistance to chemotherapy." | ( Cai, Z; Chen, J; Fu, H; Hua, Y; Li, J; Wang, Z; Yin, F, 2014) |
| "Osteosarcoma is a malignant bone tumor in children and adolescents characterized by intrinsic therapeutic resistance." | ( Chiyoda, T; Fukuchi, Y; Ikeda, H; Ishikawa, T; Kamei, J; Kamel, W; Koyama, Y; Matsuo, K; Muto, A; Nagai, T; Onishi, N; Osuka, S; Saya, H; Shimizu, T; Sugihara, E; Tamaki, S; Toguchida, J; Toyama, Y; Ueki, A; Yamaguchi-Iwai, S, 2014) |
| "Osteosarcoma is a malignancy of the bone that primarily affects adolescents." | ( Kopeček, J; Low, SA; Yang, J, 2014) |
| "Osteosarcoma is the most common type of malignant bone tumor in children and adolescents." | ( Feng, L; Feng, T; Huang, Y; Qi, W; Qiao, G; Shen, Z; Yao, Y, 2014) |
| "Osteosarcoma is the most common primary malignancy of bone." | ( Fu, WM; Hsieh, IS; Yang, RS, 2014) |
| "Osteosarcoma is the second highest cause of cancer-related death in children, mainly due to development of often fatal metastasis, usually in the lungs." | ( Chen, FY; Chen, J; Huang, GY; Shi, JS; Wang, SQ; Wei, YB; Wu, JG; Xia, J, 2014) |
| "Osteosarcoma is the most common malignant primary bone tumor in children and young adults and lung metastasis is the main cause of death in those patients." | ( Au, MK; Chang, JB; Chung, JG; Hsu, SC; Lin, JH; Lin, JP; Liu, CM; Liu, JY; Lu, HF; Shang, HS; Wu, PP, 2014) |
| "Osteosarcoma is the most common primary malignancy of the bone." | ( Gao, B; Liang, W; Qian, Y; Weng, D; Xie, M; Xu, G, 2014) |
| "Osteosarcoma is often a fatal malignancy." | ( Crowe, PJ; Goldstein, D; Wang, X; Yang, JL, 2014) |
| "Osteosarcoma is the most common, non-hematopoietic, primary bone cancer Current standard treatment is to use neoadjuvant chemotherapy followed by surgical resection." | ( Jirangkul, P; Mungthin, M; Punyaratabandhu, T; Songpattanaslip, T; Srisawat, P, 2014) |
| "Osteosarcoma is the most common type of solid bone cancer, which is the second leading cause of cancer-related death." | ( Han, XZ; Li, X; Meng, FB; Wang, W; Wang, ZX; Zhai, YQ; Zhou, DS, 2015) |
| "Osteosarcoma is the most common primary malignant tumor of bone, the long-term survival of which has stagnated in the past several decades." | ( Gao, HL; Li, BH; Li, HY; Sun, LL; Xie, T; Ye, ZM; Zhang, J; Zhang, N, 2015) |
| "Osteosarcoma is notoriously difficult to treat with standard chemotherapy, and we examined whether pharmacological inhibition of the Aven-controlled ATR-Chk1 response could sensitize osteosarcoma cells to genotoxic compounds." | ( Baranski, Z; Booij, TH; Bovée, JV; Cleton-Jansen, AM; Danen, EH; Hogendoorn, PC; Price, LS; van de Water, B, 2015) |
| "Osteosarcoma is the most common pediatric bone malignancy with high propensity to metastasize and relapse." | ( Fontes-Ribeiro, C; Gomes, CM; Gonçalves, C; Martins-Neves, SR; Oliveira, VE; Paiva-Oliveira, D, 2015) |
| "Osteosarcoma is the most common primary malignant bone tumor, and the grading of osteosarcoma cells relies on traditional histopathology and molecular biology methods, which require RNA extraction, protein isolation and immunohistological staining." | ( Chen, HF; Chiang, YH; Chiou, A; Kuo, YC; Lee, OK; Wu, SH, 2015) |
| "Osteosarcoma is the most common primary malignant bone tumor and affects a significant portion of pediatric oncology patients." | ( Chiang, J; Dmitriev, P; Hong, CS; Hu, X; Lu, J; Moon, S; Wang, H; Yang, C; Zhang, C; Zhou, Y; Zhu, D; Zhuang, Z, 2015) |
| "Osteosarcoma is a most common highly malignant bone tumor in children and adolescents." | ( Chang, J; Li, Y; Lu, S; Shi, Q; Wang, C; Wang, H; Wang, X; Wang, Y; Yang, Y; Yang, Z; Zeng, Q; Zhao, D; Zhao, Y; Zimmerman, J, 2015) |
| "Osteosarcoma is the most frequent primary malignant form of bone cancer, comprising 30% of all bone cancer cases." | ( Chang, R; Sun, L; Webster, TJ, 2015) |
| "Osteosarcoma is the main malignant primary bone tumor in children and adolescents for whom the prognosis remains poor, especially when metastases are present at diagnosis." | ( Amiaud, J; Brion, R; Heymann, D; Lamora, A; Mullard, M; Redini, F; Verrecchia, F, 2015) |
| "Osteosarcoma is a common metastatic bone cancer that predominantly develops in children and adolescents." | ( Homma, Y; Kikuchi, H; Komachi, M; Kubohara, Y; Oshima, Y, 2015) |
| "Osteosarcoma is considered the most frequent primary bone malignancy." | ( Dai, K; Dass, CR; Li, H; Ouyang, Z; Qin, A; Xu, J; Zhai, Z, 2018) |
| "Osteosarcoma is the most common of all the bone malignancies and accounts for 30-80% of the primary skeletal sarcomas." | ( Li, RY; Liu, Z; Qin, YG; Wang, CY; Wang, QY; Zhang, BY; Zhu, LY, 2015) |
| "Osteosarcoma is a very aggressive bone tumor." | ( Cacciapuoti, G; Delle Cave, D; Ilisso, CP; Illiano, M; Naviglio, S; Porcelli, M; Sapio, L; Spina, A, 2016) |
| "Extraosseous osteosarcoma is rare, and the most appropriate therapy is unclear because there are few studies regarding its treatment." | ( Fan, Z; Guadagnolo, BA; Lewis, VO; Lin, PP; Patel, S, 2015) |
| "Osteosarcoma is the most common bone cancer." | ( Baek, SJ; Fachin, AL; Lee, SH; Marins, M; Silva, G, 2016) |
| "Primary spinal osteosarcoma is quite rare, and the 5-year survival rate is very low." | ( Ozaki, T; Sugimoto, Y; Takigawa, T; Tanaka, M; Zhang, W, 2016) |
| "Osteosarcoma is the most common type of malignant bone tumour in children and adolescents; it has poor prognosis, is highly metastatic and is resistant to current therapeutic approaches." | ( Delebinski, CI; Georgi, S; Kleinsimon, S; Kopp, B; Melzig, MF; Seifert, G; Twardziok, M, 2015) |
| "Although osteosarcoma is the most common second malignancy, little is known about its clinical and therapeutic features." | ( Fujiwara, M; Fujiwara, T; Kawai, A; Numoto, K; Ogura, K; Suzuki, S; Yonemoto, T; Yoshida, A, 2015) |
| "Osteosarcoma is the most common primary bone tumor in adolescents associated with skeletal development." | ( Dorfman, H; Geller, D; Gorlick, R; Healey, JH; Hoang, BH; Mason, G; Meyers, PA; Neophytou, N; Phinney, DG; Piperdi, S; Yang, R; Zhang, Y; Zhu, Z, 2016) |
| "Osteosarcoma is a typical bone cancer that primarily affects adolescents." | ( Chen, B; Lin, XJ; Wang, LF; Yang, JZ; Zhang, YJ, 2015) |
| "Osteosarcoma is a rare tumor and any effort should be made to improve the level of International collaboration." | ( Ferrari, S; Serra, M, 2015) |
| "Osteosarcoma is composed of tumor osteoblasts and bone-like tissues, with malignant tumors originating from osteogenesis organization." | ( Chen, J; Guo, LY; Han, H; He, N; Liu, ZG; Mao, D; Wang, L; Wang, YA; Wang, ZY; Xiong, M; Xu, SJ; Yu, HL; Zeng, Y, 2016) |
| "Small cell osteosarcoma is a rare tumour that histologically mimics Ewing sarcoma, mesenchymal chondrosarcoma and lymphoma, the presence of osteoid being diagnostic." | ( Agarwal, S; Bakhshi, S; Bhalla, A; Gahlot, GP, 2015) |
| "Osteosarcomas are aggressive bone tumours with a high degree of genetic heterogeneity, which has historically complicated driver gene discovery." | ( Andreou, D; Baumhoer, D; Bielack, S; Blattmann, C; Burdach, S; Castro-Giner, F; Dürr, HR; Engert, F; Fulda, S; Heinimann, K; Jundt, G; Korbel, JO; Kovac, M; Kovacova, M; Krieg, A; Kulozik, A; Melcher, I; Mueller, NS; Nathrath, M; Rechl, H; Ribi, S; Schaser, KD; Smida, J; Specht, K; Tomlinson, I; Tunn, PU; Weischenfeldt, J, 2015) |
| "Osteosarcoma is the most common type of primary malignant tumor of the bone." | ( Ji, F; Sun, J; Tang, H; Xie, Y; Xu, Y; Yue, H, 2016) |
| "Osteosarcoma is the most common primary malignant bone tumor, and the frequent acquisition of chemoresistance is often an obstacle to achieving favorable outcomes during chemotherapy." | ( Ding, M; Huang, J; Jin, Q; Liu, K; Ni, J; Song, D; Wang, J, 2016) |
| "Osteosarcoma is the most common primary malignant bone tumour." | ( Bovée, JV; Cleton-Jansen, AM; Gelderblom, H; Reitsma, PH; Ruf, W; Tieken, C; Verboom, MC; Versteeg, HH, 2016) |
| "Osteosarcoma is the second most common primary tumor of the skeletal system and the most common primary bone tumor." | ( Bartholomew, A; Beard, B; Garces, J; Mathkour, M; Sulaiman, OA; Ware, ML, 2016) |
| "Osteosarcoma is a highly malignant neoplasm." | ( Bartholomew, A; Beard, B; Garces, J; Mathkour, M; Sulaiman, OA; Ware, ML, 2016) |
| "Osteosarcoma is the most common bone sarcoma in adolescents and children." | ( Agrawal, A; Purandare, N; Rangarajan, V; Shah, S; Verma, P, 2016) |
| "Osteosarcoma is the most common primary malignant tumor of the bone." | ( Lin, HQ; Mao, JP; Ren, HY; Wang, SD; Xie, T; Ye, ZM; Zhu, T, 2016) |
| "Osteosarcoma is one of the most malignant bone tumors of childhood and adolescence." | ( Gorska, M; Kuban-Jankowska, A; Wozniak, M; Wyszkowska, RM, 2016) |
| "BACKGROUND Osteosarcoma is one of the most common malignant bone cancers worldwide." | ( Chen, Z; Guo, Q; Wu, J, 2016) |
| "Osteosarcoma is the second highest cause of cancer-related death in children and adolescents." | ( Bi, Z; Cao, Y; Chen, Y; Liu, T; Liu, Z; Lu, Y; Peng, Y; Shan, H; Wang, L; Yang, L; Zhou, Y, 2016) |
| "Osteosarcoma is the most common bone malignancy in children and adolescents, and 20%-30% of the patients suffer from poor prognosis because of individual chemoresistance." | ( Bi, WZ; Han, G; Huang, JQ; Jia, JP; Mao, BB; Wang, DY; Wang, W; Wu, YN; Xu, M, 2016) |
| "Osteosarcoma is the most common primary bone tumour in children and adolescents." | ( Bi, Z; Geng, S; Gu, L; Ju, F; Tang, H; Wang, Y; Yang, C; Zhang, H, 2016) |
| "Osteosarcoma is the primary cancer of leaf tissue and is regarded as a differentiation disease caused by genetic and epigenetic changes which interrupt the osteoblast differentiation from mesenchymal stem cells." | ( Cao, W; Dai, L; Liang, W; Liu, Z; Qin, S; Xiong, X; Ye, D; Zhang, J, 2016) |
| "Osteosarcoma is the major malignant primary bone cancer in children and adolescents, which is highly aggressive with frequent acquisition of chemoresistance phenotypes." | ( Bi, ZG; Cao, Y; E, XQ; Ji, G; Liu, W; Wang, DW; Wu, L; Yang, L, 2017) |
| "Osteosarcoma is a rare disease diagnosed as malignant bone tumor." | ( Fujiwara, T; Hasei, J; Kagawa, S; Komatsubara, T; Kunisada, T; Omori, T; Osaki, S; Ozaki, T; Sasaki, T; Sugiu, K; Tazawa, H; Urata, Y; Yamakawa, Y; Yoshida, A, 2016) |
| "Osteosarcomas are aggressive with a high incidence of recurrence and metastasis." | ( Chen, WW; Cheng, MF; Chou, YH; Ko, KY; Yen, RF, 2016) |
| "Osteosarcoma is an aggressive bone cancer that has a high propensity for metastasis to the lungs." | ( Bode-Lesniewska, B; Born, W; Boro, A; Fuchs, B; Gvozdenovic, A; Meier, D; Muff, R, 2016) |
| "Osteosarcoma is the most common primary malignancy of bone." | ( Botter, SM; Fuchs, B; Neklyudova, O; Pellegrini, G; Robl, B, 2016) |
| "Osteosarcoma is the most common primary bone cancer in children and is a highly malignant disease, in which 25% of patients present with metastasis at diagnosis." | ( Clemens, D; Dirksen, U; Hotfilder, M; Klco-Brosius, S; Pettke, A; Potratz, J; Schaefer, C, 2016) |
| "Osteosarcoma is the most common type of primary malignant bone tumor diagnosed in the United States among adolescents and children." | ( Baugher, PJ; Rossi, V; White, B, 2016) |
| "Osteosarcoma is the most common primary bone tumor and poor prognosis for osteosarcoma patients is mainly due to chemotherapy resistance." | ( Haigl, B; Stockhammer, V; Sutterlüty-Fall, H; Vanas, V, 2016) |
| "Osteosarcomas are highly aggressive bone tumors that mainly occur in the metaphyses of long bones in children and adolescents." | ( Baumhoer, D, 2016) |
| "Osteosarcoma is the most prevalent primary malignant bone tumor, but treatment is difficult and prognosis remains poor." | ( Deng, P; Junger, WG; Qi, B; Sun, D; Wang, C; Wang, T; Xia, Y; Yao, J; Yu, T; Zhang, X, 2016) |
| "Osteosarcoma is a high‑grade malignant tumor frequently found in children and adolescents." | ( Guo, Q; Liu, S; Liu, Y; Wang, Y; Wu, Y; Xu, H; Yang, Y; Zhang, G; Zhu, J, 2016) |
| "Osteosarcoma is the most common type of primary bone tumor, novel therapeutic agents for which are urgently needed." | ( Fukuchi, Y; Kamel, WA; Maki, K; Matsuo, K; Muto, A; Nobusue, H; Onishi, N; Saya, H; Shimizu, T; Sugihara, E; Yamaguchi-Iwai, S, 2017) |
| "Osteosarcoma is the most common malignant bone tumor that frequently affects adolescents." | ( Han, W; He, W; Jin, S; Li, J; Li, X; Lu, X; Qian, Y; Yang, W; Yang, Z, 2017) |
| "Osteosarcoma is a devastating tumor of bone, primarily affecting adolescents." | ( Kong, QJ; Ou Yang, YP; Yang, C; Yang, QO; Yuan, W, 2016) |
| "Osteosarcoma is the most frequently occurring bone cancer in children and adolescents." | ( George, E; Gorlick, R; Kolb, EA; Mason, RW; Patil, PU; Sampson, VB; Vetter, NS; Zhang, W, 2016) |
| "Osteosarcoma is a bone tumor that mainly affects children and adolescents." | ( Bravo, D; Maran, A; Sarkar, G; Shogren, KL; Wagner, ER; Yaszemski, MJ; Zuo, D, 2017) |
| "Radiation-induced osteosarcomas are a recognized complication of radiation therapy." | ( Benjaafar, N; Echchikhi, Y; Kebdani, T; Loughlimi, H; Touil, A, 2016) |
| "Osteosarcoma is the most common primary malignant bone tumor in the pediatric age group, and chemotherapy directed by targeted nanoparticulate drug delivery system represents a promising approach for osteosarcoma treatment recently." | ( Ding, F; Fang, Z; Kan, W; Li, P; Liu, M; Miao, R; Sun, Y; Xiao, H, 2017) |
| "Osteosarcoma is one of the most devastating cancers with associated poor prognosis." | ( Cao, B; Jin, H; Jin, X; Wang, W, 2017) |
| "Osteosarcoma is the most common bone tumor and is associated with a poor prognosis." | ( Delebinski, C; Eggert, A; Jaeger, S; Kauczor, G; Kleinsimon, S; Seifert, G, 2017) |
| "Osteosarcoma is the most common primary bone tumor characterized by high risk of metastasis, thus presents with an overall survival rate of 60%, despite the use of chemotherapy and surgery." | ( Chen, C; Chen, Y; Hu, Q; Li, S; Zhao, Z; Zhu, M, 2017) |
| "Osteosarcomas are malignant tumors of bone, most commonly seen in children and adolescents." | ( Ait Taouit, L; Basu-Roy, U; Gulzar, H; Houssou, M; Jaikaran, T; Kozlitina, K; Liao, S; Mahajan, SS; Mansukhani, A; Ruiz, Y; Schvarts, Y; Yelskaya, Z, 2017) |
| "Osteosarcoma is the most common primary malignancy of the musculoskeletal system, and is associated with excessive proliferation and poor differentiation of osteoblasts." | ( Gui, S; Liu, C; Ma, M; Xue, S; Zhang, J; Zhang, X, 2017) |
| "Osteosarcoma is a rare type of bone cancer affecting humans." | ( Li, AX; Li, X; Sun, M, 2017) |
| "Osteosarcoma is the most common type of bone cancer, especially in children and young adults." | ( Huo, Y; Jiao, X; Li, Q; Li, Z; Pan, X; Wang, X; Zheng, J, 2017) |
| "Osteosarcoma is the most common malignant bone tumor in children and adolescents." | ( Duan, H; Luo, Y; Min, L; Shi, R; Tang, F; Tu, C; Zhang, W; Zhou, Y, 2017) |
| "Osteosarcoma is the most frequent primary malignant bone tumor." | ( Berger, W; Heffeter, P; Keppler, BK; Kubista, B; Mayr, L; Schoefl, T; van Schoonhoven, S; Windhager, R, 2017) |
| "Canine osteosarcoma is highly resistant to current chemotherapy; thus, clarifying the mechanisms of tumor cell resistance to treatments is an urgent need." | ( Bongiovanni, L; Buracco, P; Ciccarelli, A; De Maria, R; De Martinis, M; Della Salda, L; Ginaldi, L; Malatesta, D; Maniscalco, L; Massimini, M; Palmieri, C; Romanucci, M, 2017) |
| "Osteosarcoma is suggested to be caused by genetic and molecular alterations that disrupt osteoblast differentiation." | ( Fu, XL; Ge, ZJ; Jiang, JN; Jiang, ZH; Liu, L; Peng, J; Tan, YF; Wang, JZ; Yang, HL, 2017) |
| "Osteosarcoma is the most common bone cancer, and chemotherapy is currently indispensable for its treatment." | ( Cao, H; Cao, J; He, Q; Huang, P; Li, W; Shao, X; Xian, M; Yang, B; Ying, M; Zhang, N; Zhu, D, 2017) |
| "Osteosarcoma is the most common malignant bone tumor." | ( Han, W; He, W; Jin, S; Li, J; Li, X; Lu, X; Qian, Y; Yang, W; Yang, Z, 2017) |
| "Osteosarcoma is the most common primary malignant bone tumor." | ( Cai, Z; Fu, Z; Hua, Y; Li, S; Lin, B; Wang, Z; Yang, Q; Zhou, Z, 2017) |
| "Osteosarcoma is the most common type of primary bone tumor, and novel therapeutic approaches for this disease are urgently required." | ( Fukuchi, Y; Kamel, WA; Muto, A; Saya, H; Shimizu, T; Yamaguchi-Iwai, S, 2017) |
| "Osteosarcoma is an aggressive malignant bone tumor that causes bone destruction." | ( Fujiwara, T; Hasei, J; Kagawa, S; Komatsubara, T; Kunisada, T; Omori, T; Osaki, S; Ozaki, T; Sugiu, K; Tazawa, H; Uotani, K; Urata, Y; Yamakawa, Y; Yoshida, A, 2017) |
| "Osteosarcoma is the predominant form of primary bone malignancy." | ( Bi, Z; Chen, Y; Geng, S; Liu, R; Sun, J; Tu, H; Wang, X; Zhang, Y; Zou, J, 2017) |
| "Osteosarcoma is the most common primary bone tumor that occurs in children and adolescents." | ( Chao, CC; Chen, PC; Hou, CH; Hou, SM; Huang, CC; Liu, JF, 2017) |
| "Osteosarcoma is a common bone tumor which is affected by E2, the most representative estrogen." | ( Lv, M; Qi, W; Song, D; Tian, K; Yan, Q; Zhang, F; Zhang, H, 2017) |
| "Osteosarcoma is the most common pediatric malignant bone tumor, frequently surgically managed with limb salvage rather than amputation." | ( Gelfand, MJ; McCarville, MB; Sharp, SE; Shulkin, BL, 2017) |
| "Osteosarcoma is the most common primary bone tumor in children and young adults." | ( Avan, A; de Sá Lopes, AC; Dos Santos Cavalcanti, A; Gholamin, S; Hanae Kasai Brunswick, T; Kahn, SA; Leite Duarte, ME; Matheus Guimarães, JA; Meohas, W; Razavi, M; Ribeiro, GO, 2017) |
| "Osteosarcoma is a malignant tumor associated with high mortality; however, no effective therapies for the disease have been developed." | ( Bai, B; Fan, P; Hong, W; Lan, H; Qian, D; Zhu, J, 2017) |
| "Osteosarcomas are highly malignant tumors, which develop rapid growth and local infiltration, inducing metastases that spread primarily in the lung." | ( Arcadio, V; Biasiucci, M; Cortese, B; D'Amone, S; Gigli, G; Palamà, IE, 2017) |
| "Osteosarcoma is the most frequent primary bone tumor originating from adolescents and young adults." | ( Guan, Y; Li, DD; Song, YD; Wang, YL; Zheng, J, 2017) |
| "Osteosarcoma is one of the most malignant neoplasms in adolescents, and it generally develops multidrug resistance." | ( Fang, W; Liang, C; Liu, B; Shao, J; Tao, H; Wang, J; Wang, Y; Xia, K; Yu, W; Zhou, C; Zhu, J, 2017) |
| "Osteosarcoma is the most common primary malignancy in bone." | ( Li, QC; Wang, T; Wang, X; Wu, J; Xu, H, 2017) |
| "CASE REPORT Osteosarcoma is a highly aggressive primary bone tumor of childhood and adolescence." | ( Hori, Y; Matsuda, S; Okamoto, T; Sakamoto, A; Shimizu, A; Yamashita, M, 2017) |
| "Osteosarcoma is the most common primary bone tumour appearing in children and adolescents." | ( Abrunhosa, AJ; Fontes-Ribeiro, C; Gomes, CMF; Martins-Neves, SR; Paiva-Oliveira, DI, 2018) |
| "Osteosarcoma is an aggressive bone tumor characterized by biological and molecular heterogeneity, possibly dependent on CSCs." | ( Bajetto, A; Barbieri, F; Campanella, C; Corsaro, A; Daga, A; De Maria, R; Ferrari, A; Florio, T; Gatti, M; Maniscalco, L; Pattarozzi, A; Ratto, A; Solari, A; Thellung, S; Würth, R, 2018) |
| "Osteosarcoma is a common primary malignant bone tumor, the cure rate of which has stagnated over the past 25-30 years." | ( Cai, W; He, P; Tan, M; Wang, B; Wu, B; Zhang, X, 2018) |
| "Osteosarcoma is the most common high-grade human primary malignant bone sarcoma with lower survival in the past decades." | ( Dong, X; Jiang, X; Lu, Y; Ma, B; Sun, Y; Yu, L; Zhang, J; Zhang, Q; Zhu, J, 2018) |
| "Osteosarcoma is the most common primary malignant tumor of bone, the long-term survival of which has stagnated in the past several decades." | ( Chen, Y; Fang, X; Huang, K; Ma, Y; Shen, S; Wu, Y; Zhang, R, 2018) |
| "Osteosarcoma is one of the most common malignant tumors in adolescent populations and the prognosis remains incompletely understand." | ( Jiang, K; Yu, B; Zhang, J, 2018) |
| "Osteosarcoma is the most common primary bone tumor in children and adolescents." | ( Jia, Q; Li, W; Liu, W; Shen, J; Su, Q; Wang, Y; Yin, J; Zhang, J; Zhang, X; Zhao, Z, 2018) |
| "Osteosarcoma is the leading primary bone cancer in young adults and exhibits high chemoresistance rates." | ( Hanschen, M; Kalbitz, M; Kany, S; Kneip, N; Relja, B; Sturm, R; Woschek, M, 2018) |
| "Canine osteosarcoma is an aggressive primary bone tumor that shows metastasis to distal regions and is associated with a high mortality rate." | ( Bazer, FW; Lim, W; Park, H; Park, S; Song, G, 2018) |
| "Osteosarcoma is a common primary malignant bone tumor that mainly occurs in childhood and adolescence." | ( Cheng, AY; Dai, G; Guo, W; Yang, J; Zheng, D, 2018) |
| "Osteosarcoma is the most common primary malignancy of bone in children and the elderly." | ( Bai, F; Dong, Z; Guo, Y; Li, Y; Lu, J; Xiao, Y, 2018) |
| "Osteosarcoma is the most common primary bone tumor in children, and only 1 article in the literature describes a case of osteosarcoma in a patient with Down syndrome." | ( Nath, A; Sims, E; Sugalski, A, 2019) |
| "Osteosarcoma is an aggressive malignancy that usually occurs in children and young adults, and long-term survival is only about 20% in patients with metastasis or recurrent disease." | ( Guan, Z; Zhang, X, 2018) |
| "Osteosarcoma is an aggressive malignant neoplasm, which commonly afflicts patients of 20-30 years of age, and its morbidity has increased markedly in recent years." | ( Li, YL; Yang, BH; Yu, C; Yu, XR; Zhang, B; Zhao, JL; Zhen, O, 2018) |
| "Osteosarcoma is the most common malignant bone tumor that occurs in children and adolescents." | ( Gu, R; Sun, Y, 2018) |
| "Osteosarcoma is a common primary malignant bone tumour, and its cure rate has stagnated over the past 25-30 years." | ( He, P; Kang, Y; Li, X; Wang, H; Wu, B; Xie, P; Ye, Y, 2018) |
| "Osteosarcoma is the most common primary malignant tumor of the bone found predominantly in children and teenagers and results in early metastasis and poor prognosis." | ( Chen, Y; He, B; Liu, H; Ou, Y; Tao, Y; Yin, H; Yu, H; Zhao, Z; Zhong, S, 2018) |
| "Extraskeletal osteosarcomas are uncommon entities in clinical practice, which account for 1% to 2% of all soft tissue sarcomas." | ( Luo, QY; Qiu, ZL; Shen, CT; Sun, ZK, 2018) |
| "BACKGROUND Osteosarcoma is a prevalent type of bone tumor mainly reported in children and adolescents." | ( Hu, J; Zhou, Y, 2018) |
| "Osteosarcoma is the most common bone malignancy, and it seriously affects the quality of life of affected children and adolescents." | ( Fan, S; Fang, X; Jie, Z; Pan, X; Qin, A; Shen, S; Sun, X; Xie, Z; Yu, H; Zhao, X, 2019) |
| "Osteosarcoma is the most common primary bone tumor in children and adolescents." | ( Guo, S; Guo, Z; Ke, X; Li, X; Li, Y; Liu, Y; Shen, C; Wang, W; Xiao, X; Yang, D, 2018) |
| "BACKGROUND Osteosarcoma is the most common primary bone malignancy and often presents at an early age." | ( Qian, W; Sun, H; Yin, H; Yin, M, 2018) |
| "Metastatic osteosarcoma is largely treated with high-dose methotrexate (HDMTX)-based therapy, especially in the pediatric population." | ( Bajpai, J; Banavali, S; Chandrasekharan, A; Ghosh, J; Gupta, S; Karpe, A; Pandey, N; Rekhi, B; Simha, V; Singh, A; Talreja, V; Vora, T, 2018) |
| "Osteosarcoma is the most common primary bone tumor with highly invasive characteristic and low long-term survival." | ( Jiang, X; Lu, Y; Ma, B; Sun, Y; Yu, L; Zhang, Q; Zhu, J, 2018) |
| "Osteosarcoma is the most common primary malignant tumor of bone in children and adolescents." | ( Argenziano, M; Casale, F; Di Paola, A; Di Pinto, D; Pota, E; Punzo, F; Rossi, F; Tortora, C, 2018) |
| "Extraskeletal osteosarcoma is a rare, high-grade soft tissue malignancy, accounting for approximately 1% of all soft tissue sarcomas." | ( Goni, V; Kumar, R; Mittal, BR; Parihar, AS; Sood, A; Vadi, SK, 2018) |
| "Osteosarcoma is the most common bone cancer." | ( Cai, Z; Jewison, DE; Maran, A; Miller, AL; Okuno, SH; Shogren, KL; Waletzki, BE; Yaszemski, MJ; Zang, J; Zuo, D, 2018) |
| "Osteosarcoma is the most frequent primary bone tumor." | ( Han, S; Liu, J; Sun, K; Wang, A; Wu, D; Yin, B; Zhang, W; Zhou, M, 2019) |
| "Osteosarcoma is the most common malignant bone tumor in children and young adults that produces aberrant osteoid." | ( Alonso, MM; Collantes, M; Ecay, M; García-Velloso, MJ; Marrodán, L; Martínez-Vélez, N; Patiño-García, A; Peñuelas, I; Zalacain, M, 2018) |
| "Osteosarcoma is the most common primary malignant bone tumor." | ( D'Acunto, M; D'Alessandro, D; Danti, S; Trombi, L, 2018) |
| "Osteosarcoma is a malignant primary bone tumor that responds poorly to both chemotherapy and radiation therapy." | ( Chang, TM; Chi, MC; Lee, CW; Liu, JF, 2019) |
| "Osteosarcoma is the most common primary malignant bone tumour, but the survival rate of patients has plateaued since the mid-1980s." | ( Cao, J; He, QJ; Huang, C; Qi, XT; Shao, XJ; Wang, C; Xu, T; Yang, B; Yang, XC; Ying, MD; Zhang, N; Zhu, H, 2019) |
| "Osteosarcoma is the most frequent malignant primary bone tumor, and it generally develops a multidrug resistance." | ( Kong, LY; Xia, Y; Xue, GM; Yang, L; Zhang, C; Zhang, H; Zhuo, FF, 2019) |
| "Osteosarcoma is the most common type of primary malignant bone tumor, with extremely poor prognosis in patients with metastatic disease and resistance to therapy, such as multidrug regimens." | ( Chen, R; Gao, YY; Huang, LH; Wang, Y; Yang, JZ, 2019) |
| "Osteosarcoma is the most common cancer in bone." | ( Caliskan, Y; Dalgic, AD; Gerekci, S; Gulec, EA; Keskin, D; Ozen, C; Tezcaner, A, 2019) |
| "Osteosarcoma is a malignant tumor in the bone, which originates from normal osteoblasts or osteoblast precursors." | ( El Ayachi, I; Fatima, I; Garcia-Lopez, J; Khalid, AB; Krum, SA; Kumpati, J; Lillo Osuna, MA; Miranda-Carboni, GA; Seagroves, TN; Slayden, AV, 2019) |
| "Osteosarcoma is recognized as the most common primary malignant bone tumor, the 5-year disease-free survival rate in patients with metastatic or recurrent disease is below than 30%." | ( Ji, XF; Li, ZZ; Wang, YL; Xing, YL; Yu, YH, 2019) |
| "Canine osteosarcoma is a devastating disease with an overall poor prognosis." | ( Boston, S; Hoddinott, K; Mutsaers, AJ; Oblak, ML; Wood, GA, 2019) |
| "Osteosarcoma is the most common primary malignancy of bone and characterized by an appendicular primary tumor with a high rate of metastasis to the lungs." | ( Chen, H; Fan, C; Fang, A; Luo, Y; Song, L; Tu, C; Xie, Y; Ye, T; Zeng, A; Zeng, C, 2019) |
| "High-grade osteosarcoma is a primary malignant bone tumour mainly affecting children and young adults." | ( Anninga, J; Antal, I; Arndt, C; Bernstein, M; Bielack, SS; Brown, KLB; Butterfass-Bahloul, T; Calaminus, G; Capra, M; Dhooge, C; Eriksson, M; Flanagan, AM; Friedel, G; Gebhardt, MC; Gelderblom, H; Goldsby, R; Gorlick, R; Grier, HE; Grimer, R; Hawkins, DS; Hecker-Nolting, S; Hogendoorn, P; Ingleby, FC; Isakoff, MS; Janeway, KA; Jovic, G; Kabickova, E; Kager, L; Krailo, MD; Kühne, T; Lang, S; Lau, CC; Leavey, PJ; Lessnick, SL; Marina, N; Mascarenhas, L; Mayer-Steinacker, R; Meyers, PA; Nagarajan, R; Randall, RL; Rechnitzer, C; Reichardt, P; Renard, M; Schwartz, CL; Smeland, S; Strauss, S; Sundby Hall, K; Sydes, MR; Teot, L; Timmermann, B; von Kalle, T; Whelan, J, 2019) |
| "Osteosarcoma is the most common primary malignant bone tumor in children and adolescents, with highly aggressive behavior and early systemic metastasis." | ( Cai, Z; Duan, Z; Fu, Z; Hua, Y; Jiang, Y; Mao, M; Sang, W; Sun, M; Sun, W; Wang, C; Wang, G; Wang, H; Wang, Z; Xu, J; Yin, F; Zhang, T; Zhou, Z; Zuo, D, 2019) |
| "Osteosarcoma is a malignant primary bone tumor, which often associates with pulmonary metastasis." | ( Cheng, L; Dai, Y; Li, Z; Lin, Z; Long, H; Luo, Z; Sun, B; Tang, Y; Xiong, Z; Xu, X; Yu, K; Zeng, M; Zhang, Y; Zhao, S; Zhu, J; Zhu, Y, 2019) |
| "Osteosarcoma is the primary human malignant tumor affecting bone." | ( Bode, AM; Chen, H; Dong, Z; Gorja, DR; Guo, Z; Jin, G; Liu, F; Liu, K; Reddy, K; Wang, K; Yao, K; Zhao, Z, 2019) |
| "Osteosarcoma is among the most common malignant bone tumors in human skeletal system." | ( Cheng, R; Cui, W; Dai, Y; Liu, H; Ni, Q; Wu, W; Ye, T, 2018) |
| "Osteosarcoma is one of the most pernicious primary bone tumor characterized by high malignancy and metastasis, however its pathogenesis remain largely unknown." | ( Dai, X; Han, X; He, X; Ma, W; Wang, Y; Yao, L, 2019) |
| "Osteosarcoma is the most common primary malignant bone tumor." | ( Cai, Z; Hua, Y; Mao, M; Shen, J; Sun, W; Wang, G; Wang, H; Wang, Z; Xu, J; Yin, F; Zhang, T; Zhou, Z; Zuo, D, 2019) |
| "Recurrent osteosarcoma is a chemotherapy-resistant disease." | ( Bouvet, M; Chawla, SP; Hayashi, K; Higuchi, T; Hoffman, RM; Igarashi, K; Kimura, H; Miwa, S; Miyake, K; Oshiro, H; Singh, SR; Sugisawa, N; Tsuchiya, H; Yamamoto, N, 2019) |
| "Osteosarcoma is an aggressive malignant neoplasm and cancerous bone tumor." | ( Li, S; Liu, F; Pei, Y; Wang, W; Zhang, X; Zheng, K, 2019) |
| "Osteosarcoma is the most common primary bone cancer type in humans." | ( Burghammer, M; Grünewald, TA; Leithner, A; Lichtenegger, HC; Liegl-Atzwanger, B; Rennhofer, H; Zanghellini, B, 2019) |
| "However, osteosarcomas are highly heterogeneous, with many tumors exhibiting GD2 expression on <50% of the individual cells, while some tumors are essentially GD2-negative." | ( Amador Diaz, V; Bahrami, A; Butch, ER; Dearling, JLJ; Han, Y; Kim, J; Mead, PE; Mishra, JK; Packard, AB; Shulkin, BL; Snyder, SE; Stewart, E; Stoddard, SV; Tillman, H; Vāvere, AL, 2019) |
| "Osteosarcoma is one of the most malignant tumors in adolescents with severe outcomes while fluoride is one of the most abundant elements in the environment." | ( Deng, S; Guo, F; Jin, X; Li, M; Wu, G; Wu, L, 2019) |
| "Osteosarcoma is treated mainly with high‑dose methotrexate, doxorubicin, cisplatin and ifosfamide; however, 20‑30% of patients cannot be cured of metastatic disease." | ( Komiya, S; Maeda, S; Nagano, S; Nakashima, T; Saitoh, Y; Sasaki, H; Setoguchi, T; Taniguchi, N, 2019) |
| "Metachronous osteosarcoma is a rare form of osteosarcoma." | ( Ahluwalia, C; Arora, R; Rawal, G; Yadav, AK, 2019) |
| "Osteosarcoma is a mesenchymal malignant bone tumor accompanied by a high rate of lung metastasis and short survival in dogs." | ( Lim, W; Park, S; Ryu, S; Song, G, 2019) |
| "The management of osteosarcoma is challenging especially in lower-income and middle-income countries, and there is an unmet need to evolve efficient and sustainable chemotherapy regimens." | ( Bajpai, J; Banavali, S; Chandrasekharan, A; Ghosh, J; Gupta, S; Hingmare, S; Mandal, T; Rangarajan, B; Rekhi, B; Shah, K; Shetty, N; Simha, V; Vora, T, 2019) |
| "BACKGROUND Osteosarcoma is a primary bone aggressive cancer, affecting adolescents worldwide." | ( Fu, Y; Guo, Z; Tang, Y; Wang, J, 2019) |
| "Recurrent osteosarcoma is a recalcitrant disease; therefore, an improved strategy is urgently needed to provide therapy." | ( Bouvet, M; Chawla, SP; Hayashi, K; Higuchi, T; Hoffman, RM; Igarashi, K; Kimura, H; Miwa, S; Miyake, K; Oshiro, H; Singh, SR; Sugisawa, N; Tsuchiya, H; Yamamoto, N, 2019) |
| "Osteosarcoma is the most common primary malignant bone tumor in children and adolescents." | ( He, M; Ji, XL, 2019) |
| "Human osteosarcoma is the most common primary cancer of the bone." | ( Gu, S; Li, H; Liu, Q; Liu, Y; Wang, J; Wei, C, 2019) |
| "Osteosarcoma is the most common paediatric primary bone malignancy." | ( Bennett, TC; Bird, G; Brockley, L; Cooper, M; Endo-Munoz, L; Lane, A; Matigian, N; O'Connell, K; Peaston, A; Saunders, NA; Sommerville, S; Straw, RC; Thamm, DH; Thomson, M; Topkas, E; Wu, SY, 2020) |
| "Osteosarcoma is the most prevalent primary bone malignancy in children and young adults." | ( Bawa, O; da Costa, MEM; Fromigué, O; Gaspar, N; Mangelinck, A; Polrot, M; Stefanovska, B, 2019) |
| "Osteosarcoma is an aggressive malignant neoplasm, is most prevalent in teenagers and adults and current treatment approaches have reached a survival plateau and attempts to improve osteosarcoma prognosis have proven unsuccessful." | ( Chen, W; Fan, S; Huang, H; Jie, Z; Li, X; Ning, L; Pan, X; Qin, A; Wan, S; Wan, X; Wang, J; Xie, Z; Zhao, X, 2020) |
| "Osteosarcoma is a recalcitrant neoplasm which occurs predominantly in adolescents and young adults." | ( Bouvet, M; Chawla, SP; Han, Q; Hayashi, K; Higuchi, T; Hoffman, RM; Igarashi, K; Kimura, H; Miwa, S; Miyake, K; Oshiro, H; Park, J; Razmjooei, S; Singh, SR; Sugisawa, N; Tan, Y; Tsuchiya, H; Yamamoto, N; Zhang, Z, 2019) |
| "Osteosarcoma is a recalcitrant disease treated with surgery and intensive chemotherapy as standard." | ( Bouvet, M; Hoffman, RM; Hsu, J; Igarashi, K; Kanaya, F; Kawaguchi, K; Kiyuna, T; Li, Y; Miyake, K; Murakami, T; Nelson, S; Oshiro, H; Singh, M; Singh, SR; Tome, Y, 2019) |
| "Osteosarcoma is a rare but recalcitrant type of bone cancer." | ( Belt, P; Bouvet, M; Chawla, SP; Hayashi, K; Higuchi, T; Hoffman, RM; Igarashi, K; Kimura, H; Kline, Z; Miwa, S; Miyake, K; Oshiro, H; Singh, SR; Sugisawa, N; Tsuchiya, H; Yamamoto, N, 2019) |
| "Osteosarcoma is one of malignant cancer." | ( Kong, D; Ying, B; Ying, H; Zhang, J, 2019) |
| "Osteosarcomas are the most commonly occurring malignant bone cancer in young individuals." | ( Fang, J; Mahajan, SS; Matsui, H; Raghubir, M; Rahman, CN, 2020) |
| "Osteosarcoma is the most malignant type of bone tumor." | ( Ashihara, E; Hosogi, S; Ishida, Y; Nakamura, S; Sueyoshi, M; Sugiyama, Y; Tamai, S; Toda, Y; Yano, Y; Yoshizawa, M, 2019) |
| "Osteosarcoma is the most frequently diagnosed primary malignant bone sarcoma in children and adolescents." | ( Che, J; Luo, J; Peng, S; Shang, P; Wang, F; Wang, Y; Zhang, G; Zhao, B; Zhou, L, 2019) |
| "Osteosarcoma is the most common type of malignant bone cancer and results in cancer‑related deaths among adolescents." | ( Chen, J; Han, J; Weng, Q; Zhang, Y, 2020) |
| "Osteosarcoma is one of the most malignant bone tumors, and its major threats are aggressive invasion and early tumor metastasis, which result in a poor prognosis and high mortality." | ( Chen, K; Chen, T; Hou, Y; Jiang, Y; Jiao, J; Liang, Z; Ma, Z; Qian, L; Ren, Q; Sun, B; Wang, Y; Xue, J, 2020) |
| "Osteosarcoma is one of the most common types of primary bone cancers." | ( Bose, S; Koski, C; Sarkar, N, 2020) |
| "Osteosarcoma is a malignant tumor in bones that is common in children and adolescents." | ( Liu, HL; Liu, JS; Long, SZ; Lu, Y; Zhang, J; Zhang, T; Zhou, L, 2020) |
| "Osteosarcoma is the most common type of primary malignant bone tumor." | ( Chen, G; Jia, S; Kang, X; Lu, L; Lu, Y; Ma, Z; Shi, A; Wang, X; Yang, J; Yang, Y, 2020) |
| "Osteosarcoma is the most common malignant bone tumor in adolescence and childhood." | ( Hamada, K; Imura, Y; Naka, N; Nakai, S; Nakai, T; Outani, H; Takenaka, S; Yamada, S; Yasuda, N; Yoshikawa, H, 2020) |
| "Extraskeletal osteosarcoma is a very rare tumor with poor prognosis." | ( Kawamoto, J; Matsuyama, N; Uchi, R; Yamada, H, 2019) |
| "Osteosarcoma is the most common bone sarcoma in adolescents." | ( He, R; Liang, T; Lu, Y; Ren, J; Wang, K; Wang, Z; Xiao, D; Zhu, L, 2020) |
| "Osteosarcoma is a common, highly malignant tumor of the musculoskeletal system in young people." | ( Guo, W; Huang, Y; Liang, X; Niu, J; Ren, T; Sun, K; Wang, W; Yu, Y; Zhang, H, 2020) |
| "Osteosarcoma is the most common primary malignant tumor of the bone and the long‑term survival of patients with this disease has remained unsatisfactory over the past several decades." | ( Chen, S; Chen, T; Li, H; Lin, P; Wang, S; Wang, Z; Yao, Y; Ye, Z, 2020) |
| "Osteosarcoma is the most common primary bone malignancy that occurs frequently in children and adolescents." | ( Örenlili Yaylagül, E; Ülger, C, 2020) |
| "Osteosarcoma is considered as one of the most common types of bone tumors, which occurs among adolescents and children." | ( Chen, J; Han, J; Weng, Q; Zhang, Y, 2020) |
| "Osteosarcoma is the most common bone tumor, mainly affecting adolescents and young adults, and metastatic disease has poor outcomes with a dismal overall survival." | ( Cruz-Ramos, M; Fernández-Torres, J; López-Reyes, A; Martínez-Flores, K; Martínez-Nava, G; Medina-Luna, D; Solca, F; Zamudio-Cuevas, Y, 2020) |
| "Osteosarcoma is a highly metastatic primary bone tumor that predominantly affects adolescents and young adults." | ( Blank, B; Kallis, MP; Maloney, C; Soffer, SZ; Steinberg, BM; Symons, M, 2020) |
| "Osteosarcoma is the most frequent and intractable malignancy of the bone in children and young adults." | ( Machihara, K; Namba, T, 2020) |
| "Osteosarcoma is the most common malignant bone tumour and the second leading cause of cancer‑related death in children and adolescents." | ( Chen, L; Cheng, S; Li, B; Lin, Z; Wang, M; Wang, W; Yao, M; Yin, Q; Zhang, Y, 2020) |
| "Osteosarcoma is a malignant bone tumor and is generally treated with radiotherapy combined with radiosensitizers." | ( Du, G; Wang, D; Wang, J; Zhang, KF; Zhao, J, 2020) |
| "Osteosarcoma is one of the most common malignant bone tumors with the annual global incidence of approximately four per million." | ( Chen, G; He, M; Liu, Y; Wu, X; Xi, Y, 2020) |
| "Osteosarcoma is the most common primary malignant tumor of the skeleton in teenagers and young adults and continues to confer a generally poor prognosis in patients who do not respond to chemotherapy or who present with metastatic diseases at diagnosis." | ( Lin, CW; Lu, EW; Lu, KH; Yang, JS; Yang, SF, 2020) |
| "Osteosarcoma is a highly malignant disease and is associated with a poor patient prognosis and a high mortality rate." | ( Duan, Y; Hu, K; Ni, S; Qi, W; Tian, G; Xie, W; Yan, S, 2020) |
| "Osteosarcoma is a common malignant bone cancer easily to metastasize." | ( Cao, J; Chen, CY; Du, W; He, ZH; Hong, CG; Hu, XK; Huang, J; Liu, HM; Liu, YW; Liu, ZZ; Luo, MJ; Luo, ZW; Qian, YX; Rao, SS; Situ, WY; Tan, YJ; Tang, SY; Wang, Y; Wang, YY; Wang, ZX; Wu, B; Xia, K; Xie, H; Yan, ZQ; Yin, H; Yue, T; Zhang, HQ; Zhang, Y; Zhou, JH, 2020) |
| "Osteosarcoma is the most common primary malignant bone tumor among children and young people and is associated with poor prognosis." | ( Huang, T; Wang, H; Zhang, X, 2020) |
| "Osteosarcoma is among the most common cancers in young patients and is responsible for one-tenth of all cancer-related deaths in children." | ( Globig, P; Luthringer-Feyerabend, BJC; Martini, F; Mazzoni, E; Willumeit-Römer, R, 2020) |
| "Osteosarcoma is the most common malignant bone tumor in children and young adults, and it has a survival rate of only 60% with current cytotoxic chemotherapy combined with aggressive surgery." | ( Han, X; Hang, K; Hu, H; Li, J; Li, W; Li, Y; Tian, W; Xin, Z; Xu, R; Zhao, J, 2020) |
| "Osteosarcoma is a highly invasive primary malignant bone tumor." | ( Fan, CD; Hou, YJ; Sun, BL; Sun, JY; Wang, FZ; Yang, MF; Yin, YB; Zhang, YY, 2020) |
| "Osteosarcoma is usually F-FDG-avid." | ( Lan, X; Qin, C; Shao, F, 2020) |
| "Osteosarcoma is a malignant condition affecting adolescents and children more than adults." | ( Song, JX; Yuan, BS; Yuan, Y; Zhang, MN, 2020) |
| "Osteosarcoma is the most common type of bone cancer in adolescents." | ( de Necochea-Campion, R; Duerksen-Hughes, P; Janjua, A; Mirshahidi, HR; Mirshahidi, S; Reeves, ME; Shields, TG; Williams, NL; Yuan, X; Zuckerman, LM, 2021) |
| "Osteosarcoma is the most frequently occurring cancer in children as well as young adolescents and the metastatic forms worsen this condition to a further great extent." | ( Mishra, R; Nathani, S; Roy, P; Sircar, D; Varshney, R, 2020) |
| "Extraskeletal osteosarcoma is a malignant tumour composed of an osteoid and/or cartilaginous matrix; it arises in soft tissues without connection to the skeleton, and to our knowledge, this type of tumour is extremely rare." | ( Hui, J; Lin, J; Zhang, L; Zhao, H; Zhao, Y, 2020) |
| "Osteosarcoma is the most primary type of bone tumor occurring in the pediatric and adolescent age groups." | ( Gao, J; Lian, M; Liu, Y; Qian, J; Qiao, Z; Su, Y; Sun, B; Wu, F; Zhu, B; Zhu, X, 2021) |
| "Osteosarcoma is insensitive to radiation." | ( Chen, LC; Chen, MH; Liu, TY; Shueng, PW; Tung, FI; Wang, YC, 2021) |
| "Osteosarcoma is the most common primary malignant bone tumor in childhood and adolescence." | ( Bai, Y; Li, J; Qiu, R; Sun, D; Wang, L, 2020) |
| "Osteosarcoma is the most common primary bone malignancy." | ( Chen, P; Hu, J; Jian, Q; Lei, L; Lv, N; Williamson, RA; Zhang, D; Zhang, Y, 2021) |
| "Osteosarcoma is an aggressive bone tumor." | ( Argenziano, M; Di Martino, M; Di Paola, A; Di Pinto, D; Perrotta, S; Pota, E; Punzo, F; Rossi, F; Tortora, C, 2021) |
| "Osteosarcoma is a common type of bone cancers with a high rate of pulmonary recurrence." | ( Chai, Z; Chen, J; Du, C; Hu, Y; Jia, F; Liu, X; Lu, H; Ruan, L; Zhang, J; Zhou, M; Zhu, B, 2021) |
| "Osteosarcoma is the most common primary bone sarcoma and is often diagnosed in the 2nd-3rd decades of life." | ( Anderson, PM; Gennatas, S; Gulia, A; Huang, PH; Jones, RL; Smrke, A, 2021) |
| "Osteosarcoma is the most common primary malignant bone tumor, and its standard treatment is a combination of surgery and chemotherapy." | ( Abe, K; Araki, Y; Asano, Y; Hayashi, K; Higuchi, T; Igarashi, K; Ikeda, H; Miwa, S; Morinaga, S; Nojima, T; Takeuchi, A; Taniguchi, Y; Tsuchiya, H; Yamamoto, N; Yonezawa, H, 2021) |
| "Osteosarcoma is a common malignant tumor in adolescents with a low 5-year survival rate." | ( Chen, L; Cheng, J; Gao, J; Jin, S; Le, C; Li, N; Liu, H; Yan, R, 2021) |
| "Osteosarcoma is a common and primary malignant form of bone cancer with poor prognosis, and, as indicated in our study, a glutamine-dependent type of cancer." | ( Brul, S; Rijlaarsdam, DJ; Tomczak, JM; Weglarz-Tomczak, E, 2021) |
| "Osteosarcoma is the most common primary malignant bone tumor in children and adolescents." | ( Liu, C; Shu, C, 2021) |
| "Osteosarcoma is the most commonly diagnosed form of bone cancer." | ( Momin, M; Quadros, M; Verma, G, 2021) |
| "Osteosarcoma is the most common primary sarcoma of bone." | ( Cheng, DD; Guo, H; Li, SJ; Pan, Z; Wei, XJ; Yang, QC, 2021) |
| "Osteosarcoma is insensitive to traditional chemotherapy." | ( Ding, X; Fan, J; Lu, D, 2021) |
| "Osteosarcoma is common childhood tumour type of the bone." | ( Özgür, A, 2021) |
| "Osteosarcoma is the most common primary bone tumor in children, teenagers and adolescents." | ( Jiang, S; Li, S; Liu, G; Wang, W; Wang, Y; Wei, D; Zhang, Q; Zhu, X, 2021) |
| "Osteosarcoma is the most frequent malignant bone tumor." | ( Aoki, Y; Bouvet, M; Hamada, K; Han, Q; Hoffman, RM; Nishida, K; Tome, Y; Wu, NF; Yamamoto, J, 2021) |
| "Osteosarcoma is a rare type of bone cancer that affects mostly children and adolescents." | ( Aoki, Y; Bouvet, M; Hoffman, RM; Wu, NF; Yamamoto, J, 2021) |
| "Osteosarcoma is a relatively rare malignant tumor with a high incidence in young people." | ( Chen, X; Tan, X; Yao, H, 2021) |
| "Osteosarcoma is one of the most common primary bone tumour in children and young patients, and the third most common among adults." | ( Cao, S; Hao, Y; Peng, C; Ren, Z; Zhang, P; Zhu, J, 2021) |
| "Osteosarcoma is a type of bone tumor with a high degree of malignancy, and metastasis is the main challenge of osteosarcoma therapy." | ( Chen, D; Fan, T; Li, Y; Xie, X; Zhu, H, 2021) |
| "Osteosarcoma is a disease with high mortality in children and adolescents, and metastasis is one of the important clinical features of osteosarcoma." | ( Bao, H; Cai, Z; Guan, X; Ji, Y; Liu, H; Qin, G; Wang, X; Wei, A, 2021) |
| "Osteosarcoma is a primary malignant tumor of the bone and is one of the most aggressive cancers." | ( Lee, SY; Lee, YJ, 2021) |
| "Osteosarcoma is a primary form of malignant bone tumor." | ( Xiang, RM; Yan, JP, 2021) |
| "Background osteosarcoma is a rare, primary malignant bone tumour with limited available treatments for advanced or recurrent disease, resulting in a poor prognosis for patients." | ( Doi, T; Imura, Y; Iwata, S; Kawai, A; Kitano, S; Kobayashi, E; Naito, Y; Naka, N; Nakatani, F; Outani, H; Shimomura, A; Takahashi, S; Tamiya, H; Yamamoto, N; Yonemori, K, 2021) |
| "Osteosarcoma is the most frequent malignant bone neoplasm." | ( Higuchi, T; Hoffman, RM; Kanaya, F; Miyake, K; Nishida, K; Oshiro, H; Sugisawa, N; Tome, Y, 2021) |
| "Osteosarcoma is a common malignant bone tumor in clinical orthopedics." | ( Lv, H; Shang, P; Wang, S; Xue, Y; Zhang, G; Zhou, L; Zhou, S, 2021) |
| "Osteosarcoma is the most common primary malignant bone cancer, with high rates of pulmonary metastasis." | ( Ae, K; Fujita, N; Funauchi, Y; Haraguchi, M; Katayama, R; Kawaguchi, T; Koike, S; Matsumoto, S; Saito, M; Sasaki, Y; Seto, Y; Sugawara, M; Takagi, S; Takemoto, A; Ukaji, T, 2021) |
| "Osteosarcoma is a bone cancer characterized by the production of osteoid tissue and immature bone from mesenchymal cells." | ( Cappabianca, S; Caputo, C; Caraglia, M; Ferranti, P; Itro, A; Lama, S; Luce, A; Millan, PC; Sangiovanni, A; Stiuso, P, 2021) |
| "Osteosarcoma is the most common form of primary bone cancer and frequently metastasizes to the lungs." | ( Cerra, C; Harris, MA; Hawkins, CJ; Miles, MA; Shekhar, TM, 2021) |
| "Osteosarcoma is a commonly occurring bone malignancy, and it is the second most common cause of cancer deaths in adolescents and children." | ( Chen, H; Gong, J; Li, X; Shu, H; Yin, G; Zhao, L, 2022) |
| "Osteosarcoma is a frequent and extremely aggressive type of pediatric cancer." | ( Csikos, C; Hegedűs, C; Kiss, A; Polgár, Z; Regdon, Z; Virág, L, 2021) |
| "Osteosarcoma is a prevalent type of bone tumor in children and adolescents, with limited treatment and poor prognosis." | ( Bao, H; Wang, D, 2022) |
| "Osteosarcoma is a highly malignant musculoskeletal tumor that is commonly noticed in adolescent children, young children, and elderly adults." | ( Chen, CF; Chen, CM; Chen, WM; Wang, JY; Wu, PK, 2021) |
| "Osteosarcoma is the most common primary malignancy of the jaws and is treated by radical surgical resection." | ( Abdelsayed, R; Buchanan, A; Charmelo-Silva, S; Kalathingal, S, 2022) |
| "Osteosarcoma is one of the most prominent bone cancers which has a predominant occurrence in children and adolescents." | ( Li, W; Qin, C; Yan, J; Yang, Y; You, L; Zhao, Q, 2021) |
| "Osteosarcoma is the most common type of bone cancer, and metastasis is widespread decreasing the survival rate." | ( Fakhoury, VS; Inacio, KK; Oliveira, GSN; Oliveira, RC; Pagnan, AL; Pessoa, AS; Sanches, MLR; Tokuhara, CK; Ximenes, VF, 2022) |
| "Osteosarcoma is a primary bone tumor that mainly occurs in children and adolescents." | ( Liu, C; Shi, J; Wang, X; Wen, K; Zheng, J, 2022) |
| "Osteosarcoma is considered to be a highly malignant tumor affecting primarily long bones." | ( Bakopoulou, A; Johnstone, E; Michailidis, N; Michalakis, K; Papachristou, E; Tsouknidas, A; Vasilaki, D, 2021) |
| "Osteosarcoma is the most common primary bone malignancy in both children and adults." | ( Bui, NQ; Charville, GW; Ganjoo, KN; Hu, BD; Pribnow, A; Saadeh, NL; Spunt, SL; Testa, S, 2021) |
| "The prognosis of osteosarcoma is typically poor, with aggressive behavior; this, however, may be less severe in these strictly cutaneous tumors, though additional follow-up would be beneficial to determine long-term outcomes for the known cases." | ( Jerew, KS; Mehregan, DR, 2022) |
| "Osteosarcoma is a rare malignancy; however, it is still the most common primary bone tumor in adolescents and young adults." | ( Bajpai, J; Banavali, SD; Khan, SA; Kumar, VS; Mailankody, S, 2022) |
| "Osteosarcoma is a highly common malignant bone tumor." | ( Hsieh, YH; Lin, CW; Lu, KH; Yang, JS; Yang, SF; Yeh, CB; Yeh, LT, 2022) |
| "Osteosarcoma is the most prevalent primary bone malignancy in adolescents, and ferroptosis is implicated in its pathogenesis." | ( Chen, L; Wang, C; Xu, W; Xu, Z; Zhang, L, 2021) |
| "Osteosarcoma is a primary malignancy of mesenchymal origin, and its metastasis and multidrug resistance remain major problems affecting the therapeutic effect." | ( Chen, G; Chen, T; Gong, X; Huang, Y; Song, W; Zheng, X, 2022) |
| "Osteosarcoma is the most common bone sarcoma." | ( Aoki, Y; Bouvet, M; Hamada, K; Han, Q; Hoffman, RM; Kubota, Y; Masaki, N; Nishida, K; Tome, Y; Yamamoto, J, 2022) |
| "Osteosarcoma is mostly diagnosed in children and adolescents." | ( De Pinieux, G; Le Nail, LR; Narciso, B; Salaün, H; Simon, C; Vegas, H; Vinceneux, A, 2022) |
| "Osteosarcoma is the most common type of bone cancer in dogs and humans, with significant numbers of patients experiencing treatment failure and disease progression." | ( Bracha, S; Goodall, CP; Ishmael, JE; Mattos, DR; McPhail, KL; Milovancev, M; Serrill, JD; Wan, X; Weinman, MA, 2022) |
| "Osteosarcoma is a common bone malignancy in children and adolescents." | ( Duan, G; Li, W; Tang, J; Wang, B; Wang, Y; Zhu, Z, 2022) |
| "Osteosarcoma is the most common malignancy of the bone, yet the survival for patients with osteosarcoma is virtually unchanged over the past 30 years." | ( Abdelfattah, N; Chen, Y; Eedunuri, VK; Gupta, Y; Houghton, P; Hromas, R; Huang, Y; Medina, D; Meltzer, P; Nirzhor, S; Rajamanickam, S; Rao, MK; Subbarayalu, P; Timilsina, S; Vadlamudi, R; Yadav, P; Zheng, S, 2022) |
| "Osteosarcoma is considered as the most common primary malignant bone tumor in children and adolescents, and the treatments including chemotherapy and surgery were far from satisfactory." | ( Cong, M; Hou, Y; Ma, H; Si, M; Wang, D; Xia, Y, 2022) |
| "Osteosarcoma is the most common and highly malignant bone tumor in youngsters." | ( Li, X; Ni, S; Yi, X, 2022) |
| "Osteosarcoma is the most common primary bone malignancy in children and young adults, with a very poor prognosis." | ( Liu, J; Lou, C; Lv, H; Shang, P; Wang, Y; Zhen, C, 2022) |
| "Osteosarcoma is one of the most common malignant bone tumors." | ( Chen, H; Chen, Y; He, P; Hu, S; Jin, W; Liu, M; Ma, X; Peng, Y; Sun, Y; Yi, Z; Zhang, T; Zhou, W, 2022) |
| "Chondrosarcoma and osteosarcoma are the most frequently occurring bone cancers." | ( Herrera, F; Martín, V; Puente-Moncada, N; Rodríguez, C; Sánchez-Sánchez, AM; Turos-Cabal, M, 2022) |
| "Osteosarcoma is the most commonly seen type of primary malignant bone tumors in children and adolescents." | ( Chen, D; Chen, L; Fan, T; Li, Y; Lin, S; Xie, X; Zhu, H, 2022) |
| "Osteosarcoma is difficult to be resected through surgical operations without damage to the bone matrix, while chemotherapy and radiotherapy induce inevitable systemic injury." | ( He, L; Li, X; Li, Z; Lin, Q; Ma, X; Yang, B; Yang, Z; Zhao, Y; Zvyagin, AV, 2022) |
| "Osteosarcoma is the most prevalent bone cancer, and chemotherapy is still an indispensable treatment in its clinical practice." | ( Chen, T; Jin, J; Wang, J; Zhou, Q, 2022) |
| "Osteosarcoma is the most common primary bone cancer that affects mostly children and young adults." | ( Gong, Y; Wei, ZR, 2022) |
| "Osteosarcoma is an aggressive primary malignant bone tumor that occurs in childhood." | ( Chen, JH; Hsu, FT; Hsu, LC; Ku, MC; Lee, KC; Lee, YH; Li, CH; Lin, RF; Wang, WC; Yang, CC; Yueh, PF, 2022) |
| "Osteosarcoma is prevalent in children and adolescent." | ( Fei, D; Yuan, H; Zhao, D; Zhao, M, 2022) |
| "Osteosarcoma is still associated with limited response to standard-of-care therapy and alarmingly elevated mortality rates, especially in low- and middle-income countries." | ( Alonso, DF; Capobianco, CS; Ferrero, MR; Garona, J; Gottardo, MF; Sobol, NT; Solernó, LM; Vásquez, L, 2022) |
| "Osteosarcoma is a devastating malignant neoplasm that seriously threatens human health." | ( Hu, J; Jiang, L; Ma, Y; Zhang, N; Zhu, E, 2022) |
| "Osteosarcoma is amongst the most prevalent bone sarcomas and majorly afflicts children and adolescents." | ( Gomes, CMF; Martins-Neves, SR; Sampaio-Ribeiro, G, 2022) |
| "Osteosarcoma is a bone tumor with a high incidence in children and adolescents." | ( Guo, P; He, D; Jin, L; Li, M; Liu, J; Mi, T; Tan, X; Wang, J; Wei, G; Wu, X; Zhang, Z; Zhanghuang, C, 2022) |
| "Osteosarcoma is well-known for its high incidence in children and adolescents and long-term bone pain, which seriously reduces the life quality of patients." | ( Jia, Y; Lan, X; Ma, X; Su, YX; Wang, J; Wang, Y; Wen, W; Zhang, M; Zhong, J, 2023) |
| "Osteosarcoma is well-known for its high incidence in children and adolescents and long-term bone pain, which seriously reduces the life quality of patients." | ( Jia, Y; Lan, X; Ma, X; Su, YX; Wang, J; Wang, Y; Wen, W; Zhang, M; Zhong, J, 2023) |
| "Osteosarcoma is well-known for its high incidence in children and adolescents and long-term bone pain, which seriously reduces the life quality of patients." | ( Jia, Y; Lan, X; Ma, X; Su, YX; Wang, J; Wang, Y; Wen, W; Zhang, M; Zhong, J, 2023) |
| "Osteosarcoma is the most common primary malignant bone tumor in children and adolescents." | ( Chang, B; Du, SX; Li, XD; Liao, H; Xie, P; Zhang, QH; Zheng, GZ, 2023) |
| "Osteosarcoma is the most common primary malignant bone tumor in children and adolescents." | ( Chang, B; Du, SX; Li, XD; Liao, H; Xie, P; Zhang, QH; Zheng, GZ, 2023) |
| "Osteosarcoma is the most common primary malignant bone tumor in children and adolescents." | ( Chang, B; Du, SX; Li, XD; Liao, H; Xie, P; Zhang, QH; Zheng, GZ, 2023) |
| "Osteosarcomas are prevalent in children and young adults and have a high recurrence rate." | ( Dai, H; Gu, Q; Lei, Y; Li, S; Li, X; Lin, B; Wang, H; Wu, C; Xiao, C; Xie, M, 2023) |
| "Osteosarcomas are prevalent in children and young adults and have a high recurrence rate." | ( Dai, H; Gu, Q; Lei, Y; Li, S; Li, X; Lin, B; Wang, H; Wu, C; Xiao, C; Xie, M, 2023) |
| "Osteosarcomas are prevalent in children and young adults and have a high recurrence rate." | ( Dai, H; Gu, Q; Lei, Y; Li, S; Li, X; Lin, B; Wang, H; Wu, C; Xiao, C; Xie, M, 2023) |
| "Osteosarcoma is common type of bone cancer; however, the prognosis of patients with metastatic osteosarcoma is poor." | ( Ahangar, NK; Alizadeh, N; Baghbanzadeh, A; Baradaran, B; Dolatkhah, K; Khalaj-Kondori, M; Mokhtarzadeh, A; Shadbad, MA, 2023) |
| "Osteosarcoma is the most common bone tumor in children and adolescents." | ( Brand, ACAM; Coenen, MJH; Hurkmans, EGE; Te Loo, DMWM; Verdonschot, JAJ, 2022) |
| "Osteosarcoma is highly malignant." | ( An, HY; Bai, B; Sun, MX; Sun, YB, 2022) |
| "Osteosarcoma is the most common primary bone malignancy in children and adolescents; it exhibits rapid growth and a high metastatic potential and may thus lead to relatively high mortality." | ( Cai, Z; Hua, Y; Jin, X; Ma, X; Mu, H; Wang, Z; Xu, W; Zhang, T, 2023) |
| "Osteosarcoma is a malignant bone tumor that usually affects adolescents aged 15-19 y." | ( Chen, F; Chen, X; Huang, F; Jing, D; Pu, F; Shao, Z; Wu, W; Zhang, Z, 2023) |
| "Osteosarcoma is the most malignant and common primary bone tumor with a high rate of recurrence that mainly occurs in children and young adults." | ( Chen, G; Dai, H; Jiang, H; Li, D; Li, Q; Li, S; Shen, H; Xu, H; Zhang, K; Zhu, K, 2023) |
| "Osteosarcoma is the most common malignant tumor in bone and its prognosis has reached a plateau in the past few decades." | ( Ding, Q; Gao, Y; Jing, S; Ma, T; Sheng, G; Wang, T; Wu, H; Yang, Y; Zhang, R; Zhao, H, 2023) |
| "Osteosarcoma is the most common primary malignant bone tumor in adolescents and children and prone to develop lung metastasis." | ( Gao, Y; Liu, Y; Sheng, G; Wu, H; Yang, Y, 2023) |
| "Osteosarcoma is a common primary bone malignancy prevalent among adolescents and young adults." | ( Luan, F; Shen, Z; Si, Z; Yan, J, 2023) |
| "Osteosarcoma is a malignant tumor that can present with pain in the bones, joints, and local masses." | ( Jiang, W; Li, J; Luo, A; Luo, X; Qu, G; Shan, W; Xia, J; Zhang, J, 2023) |
| "Osteosarcoma is the most common malignant tumor in the skeletal system with high mortality." | ( Ding, J; Fan, J; Hu, R; Huang, R; Ju, Q; Li, R; Zhang, D, 2023) |
| "Osteosarcoma is a primary bone malignancy associated with the highest incidence rate." | ( Liu, J; Qi, Y; Wang, W; Yao, L, 2023) |
| "Potent metastatic osteosarcoma is the most common primary bone cancer in children, adolescents, and young adults." | ( Lin, CW; Lu, EW; Lu, KH; Lu, PW; Yang, SF, 2023) |
| "Osteosarcoma is one of the most common childhood bone malignancies." | ( Mehrvar, A; Mehrvar, N; Sadeghi, Y; Tashvighi, M, 2023) |
| "Osteosarcoma is the most common primary bone cancer that affects adolescents with early metastatic potential and drastically reduces their long-term survival rate if pulmonary metastases are detected at diagnosis." | ( Chou, CH; Hsieh, MC; Hsieh, YH; Huang, TY; Lu, KH; Lu, PW; Yang, JS; Yang, SF, 2023) |
| "Osteosarcoma is a highly invasive and early metastatic tumor." | ( Huang, X; Huang, Y; Jiwa, H; Luo, X; Xu, J; Zhang, J, 2023) |
| "Osteosarcoma is a malignant bone tumor with a high rate of lung metastasis and mortality." | ( Jia, ML; Liu, SY; Liu, W; Yang, H; Zeng, XF; Zhang, W; Zhu, WT, 2023) |
| "Osteosarcoma is a frequently occurring primary skeletal malignancy in the adolescent population." | ( Gill, SM; Hassan, A; Mufty, S, 2023) |
| "Osteosarcoma is the most frequent primary malignant bone tumor with an annual incidence of about 400 cases in the United States." | ( Barkauskas, DA; Chow, WY; Farrar, JE; Gerhard, D; Gorlick, R; Guerra, R; Guidry Auvil, JM; Hicks, MJ; Lau, CC; Man, TK; Meltzer, P; Nakka, M; Ng, PKS; Shen, J; Sun, JM; Taylor, AM; Xu, G; Yu, A, 2023) |
| "Osteosarcoma is a malignant bone tumor that is prone to metastasize early and primarily affects children and adolescents." | ( Choe, W; Moqbel, SAA; Ri, J; Sim, I; Su, H; Yan, W, 2023) |
| "Osteosarcoma is one of the most dangerous forms of tumors, leading to death in >90% of patients." | ( Fan, D; Heng, C; Hui, J; Ma, X; Zheng, X, 2024) |
| "Osteosarcoma is a malignant tumor with relatively high mortality rates in children and adolescents." | ( Chen, G; Chen, SL; He, P; Kuo, HC; Lai, Q; Su, T; Tu, CC; Wang, L; Wu, W, 2023) |
| "Clinically, osteosarcoma is the most common bone malignancy routinely treated with doxorubicin-based chemotherapy." | ( Fu, C; Fu, J; Hui, T; Qiu, M; Wang, C; Yang, Y; Yu, L; Yue, B; Zhang, T; Zhang, Y; Zhao, B; Zheng, B, 2023) |
| "Osteosarcoma is a common malignant bone tumor." | ( Li, G; Yan, X, 2023) |
| "Osteosarcoma is a rare primary malignant tumor of the bone characterized by poor survival rates, owing to its unclear pathogenesis." | ( Li, S; Shang, G; Xue, J; Zhang, H, 2023) |
| Excerpt | Reference |
|---|
| "Results of treatment for osteosarcoma of the extremity have been poor with metastases usually causing death within 2 years following diagnosis." | ( Hustu, O; Kumar, AP; Pratt, C; Rivera, G; Shanks, E; Smith, J, 1977) |
| "The use of hormone therapy in the treatment of osteosarcoma has never been reported, despite its demonstrated value in certain other malignancies." | ( Diamond, PE; McMaster, JH; Scranton, PE, 1975) |
| "In neoadjuvant treatment of osteosarcoma of the extremities intra-arterial (IA) instead of intravenous (IV) administration of cisplatinum (CDDP) has been advocated to improve local response and consequently increase the percentage of limb salvages and the cure rate." | ( Avella, M; Bacci, G; Battistini, A; Brach del Prevert, A; Casadei, R; Ferrari, S; Mancini, A; Picci, P; Ruggieri, P; Tienghi, A, 1992) |
| "The mean percent tumor necrosis in untreated osteosarcoma was 26." | ( Gillette, EL; LaRue, SM; Page, RL; Powers, BE; Straw, RC; Thrall, DE; Withrow, SJ, 1991) |
| "In the treatment of osteosarcoma and Ewing's sarcoma, ifosfamide has been identified as an effective drug." | ( Dirix, LY; Van Oosterom, AT, 1990) |
| "Now, the purpose of the treatment for osteosarcoma are assurance of their life and functional and beautiful limb-sparing." | ( Isii, S; Isu, K; Takeda, N; Ubayama, Y; Usui, M; Yagi, T; Yamawaki, S, 1990) |
| "Nineteen dogs were treated for osteosarcoma of the appendicular skeleton." | ( Couto, CG; Fossum, TW; Kitchell, BE; Shapiro, W; Theilen, GH, 1988) |
| "In the treatment of osteosarcoma, it is possible to differentiate between systemic therapy and local regional treatment." | ( de Vries, J; den Heeten, GJ; Dik, KJ; Elstrodt, J; Humphrey, GB; Meutstege, FJ; Misdorp, W; Oosterhuis, JW; Schraffordt Koops, H; Uges, DR, 1987) |
| "New aspects on the treatment of osteosarcoma, derived from recent publications, are discussed." | ( Cserhati, MD; Groscurth, P; Hofmann, V; Honegger, HP; von Hochstetter, A, 1983) |
| "A 20-year old man was treated for an osteosarcoma with a chemotherapy regimen that included ifosfamide, methotrexate, and doxorubicin." | ( Garcia, AA, 1995) |
| "The role of IFN in the treatment of osteosarcoma can still not be established." | ( Bauer, HC; Brosjö, O; Kreicbergs, A; Lindholm, J; Nilsonne, U; Silfverswärd, C; Strander, H; Szamosi, A, 1993) |
| "In a multicenter setting, intensive treatment of osteosarcoma according to protocol COSS-86 led to long-term disease-free survival for two thirds of patients." | ( Bielack, SS; Bieling, P; Delling, G; Epler, D; Fuchs, N; Graf, N; Heise, U; Jürgens, H; Körholz, D; Kotz, R; Salzer-Kuntschik, M; Weinel, P; Werner, M; Winkler, K, 1998) |
| "The increasing survival of children treated for osteosarcoma has led to an increase in limb sparing surgery." | ( Kaste, SC; Meyer, WH; Neel, MD; Pratt, CB; Rao, BN, 1999) |
| "The first choice of treatment plan for osteosarcoma is chemotherapy." | ( Akamatsu, N; Hamada, Y; Seki, K; Shiiki, K; Tasaka, K; Yoshikawa, H, 2000) |
| "The main cause of failure in the treatment of osteosarcoma in children is primary and secondary progression of disease." | ( Boruczkowski, D; Chybicka, A; Gołebiowski, W; Jaworski, W; Katski, K; Kazanowska, B; Kowalczyk, J; Kołecki, P; Leda, M; Liebhart, M; Wecławek-Tompol, J; Woźniak, W, 1998) |
| "Current treatment of osteosarcoma produces disappointing outcomes, and innovative therapies must be investigated." | ( Culver, KW; Swarthout, JT; Walling, HW, 2000) |
| "Current drug treatment for human osteosarcoma may include multiple chemotherapeutic agents, such as doxorubicin, cisplatin, and methotrexate." | ( Ashihara, T; Gebhardt, MC; Hirasawa, Y; Kusuzaki, K; Mankin, HJ; Takeshita, H, 2000) |
| "In the treatment of osteosarcoma of the extremity, the i." | ( Bacchini, P; Bacci, G; Bertoni, F; De Giorgi, U; Ferrari, S; Fiorentini, G; Forni, C; Longhi, A; Mercuri, M; Picci, P; Rimondini, S; Tienghi, A, 2001) |
| "The results also demonstrate that treatment of osteosarcoma cells with CDDO induces differentiation, as assessed by alkaline phosphatase activity and osteocalcin production, and that this response is abrogated in cells that overexpress CrmA." | ( Datta, R; Ito, Y; Kharbanda, S; Kufe, D; Pandey, P; Sporn, MB, 2001) |
| "We have previously shown that treatment of human osteosarcoma cells with the protonophore m-chlorophenylhydrazone (CCCP) for 6 h induces MPT and mitochondrial swelling without significant cell death." | ( Lim, ML; Minamikawa, T; Nagley, P, 2001) |
| "A protocol to treat osteosarcoma of the extremity was developed at two local institutions." | ( Camozzi, AB; Cullen, JW; Cullen, PM; Fink, K; Jamroz, BA; Kelly, CM; Odom, L; Peck, SD; Stevens, SL; Wilkins, RM, 2003) |
| "Vitamin K2 treatment of osteosarcoma cells increased mRNA levels for the osteoblast markers bone alkaline phosphatase, osteoprotegerin, osteopontin, and matrix Gla protein." | ( Blumberg, B; Errandi, J; Forman, BM; Grün, F; Inoue, S; Lin, M; Mallick, S; Pham, H; Romero, K; Sun, A; Tabb, MM; Zhou, C, 2003) |
| "Despite improvement in the treatment of osteosarcoma (OS), there are still many patients who cannot benefit from current treatment modalities." | ( Boven, E; Bras, J; Gerritsen, WR; Haisma, HJ; Kruyt, FA; Molenaar, B; Oosterhoff, D; Pinedo, HM; Schaap, GR; van Beusechem, VW; Witlox, MA; Wuisman, PI, 2003) |
| "While treatment of osteosarcoma cells with the chemotherapeutic agents doxorubicin or etoposide decreased cell viability, combination of these agents with ZOL did not significantly augment apoptosis in any of the cell lines tested." | ( Bouralexis, S; Evdokiou, A; Findlay, DM; Hay, S; Labrinidis, A, 2003) |
| "Current treatment of osteosarcoma is associated with poor prognosis, especially due to the increased risk of developing other cancers with chemotherapy." | ( Ivanov, V; Kalinovsky, T; Niedzwiecki, A; Rath, M; Roomi, MW, 2005) |
| "Here we describe that Pi treatment of human osteosarcoma U2OS cells results in a decrease of both intracellular cAMP levels and AC activity, and in a cell growth inhibition." | ( Chiosi, E; Fusco, A; Illiano, F; Illiano, G; Naviglio, S; Pagano, M; Romano, M; Senatore, G; Sorrentino, A; Sorvillo, L; Spina, A, 2006) |
| "In particular, we found that treatment of U-2 OS osteosarcoma cells with the anthracycine daunorubicin or with ultraviolet (UV-C) light resulted in a form of NF-kappaB that repressed rather than induced NF-kappaB reporter plasmids and the expression of specific anti-apoptotic genes." | ( Campbell, KJ; O'Shea, JM; Perkins, ND, 2006) |
| "We show that the treatment of human osteosarcoma cell lines with a new pyrazolo[3,4-d]pyrimidine derivative Src inhibitor, namely SI-83, impaired cell viability, with a half-maximal inhibitory concentration of 12 microM in nonstarved cells and a kinetic different from that known for the Src inhibitor PP2." | ( Angelucci, A; Bernardini, G; Bologna, M; Botta, M; Collodel, G; Di Stefano, A; Magrini, D; Manetti, F; Orlandini, M; Santucci, A; Schenone, S; Serchi, T; Spreafico, A; Tintori, C, 2008) |
| "The neoadjuvant treatment of osteosarcoma using intravenous agents has resulted in survival rates of 55% to 77% [3, 5, 6, 20, 22, 35]." | ( Camozzi, AB; Hinshaw, I; Hugate, RR; Kelly, CM; Madsen, W; Wilkins, RM, 2008) |
| "In conclusion, the topical treatment of osteosarcoma with KP decreased the expression of MMP-2 and VEGF, thus resulting in the suppression of tumor growth and pulmonary metastasis." | ( Aizawa, J; Kamei, S; Masuno, H; Miyawaki, J; Miyazaki, T; Norimatsu, Y; Sakayama, K; Tamashiro, S; Yamamoto, H, 2009) |
| "Nowadays single agent treatment of osteosarcoma is considered inadequate." | ( de Camargo, B; van Dalen, EC, 2009) |
| "Furthermore, co-treating osteosarcoma cells with OPG protein did not further enhance 2-ME-mediated anti-tumor effects." | ( Benedikt, MB; Mahlum, EW; Maran, A; Shogren, KL; Spelsberg, TC; Subramaniam, M; Yaszemski, MJ, 2010) |
| "Moreover, 8 cases/16 untreated osteosarcomas were CD31-negative, but the other 8 showed an high expression of CD31." | ( Carlo, B; Fabbriciani, C; Maccauro, G; Rosa, MA; Rossi, B; Scaramuzzo, L; Schinzari, G; Signorelli, D, 2010) |
| "The use of neo-adjuvant chemotherapy in treating osteosarcoma has improved patients' average 5 year survival rate from 20% to 70% in the past 30 years." | ( Amiji, MM; Choy, E; Duan, Z; Hornicek, FJ; Iyer, AK; Mankin, H; Milane, L; Ryu, K; Susa, M, 2010) |
| "Thirty-one treatment-naïve osteosarcoma patients received three cycles of neoadjuvant chemotherapy followed by surgery during 2006-2008." | ( Bajpai, J; Bakhshi, S; Gamnagatti, S; Khan, SA; Kumar, R; Malhotra, A; Rastogi, S; Safaya, R; Sharma, MC; Sreenivas, V, 2011) |
| "In the treatment of osteosarcoma, the chemotherapeutic effect influences decisions regarding the surgical margin, continuation of chemotherapy, and choice of anticancer drugs for further chemotherapy." | ( Hayashi, K; Miwa, S; Nishida, H; Ooi, A; Shirai, T; Sumiya, H; Takeuchi, A; Taki, J; Tsuchiya, H, 2011) |
| "Nowadays single agent treatment of osteosarcoma is considered inadequate." | ( de Camargo, B; van As, JW; van Dalen, EC, 2011) |
| "The standard treatment of osteosarcoma includes cisplatin and high-dose methotrexate (HDMTX); both agents exert significant toxicity, and HDMTX requires complex pharmacokinetic monitoring and leucovorin rescue." | ( Billups, CA; Daw, NC; Jenkins, JJ; Luchtman-Jones, L; Neel, MD; Quintana, J; Rao, BN; Santana, VM; Villarroel, M; Wu, J, 2011) |
| "Finally, treatment of POS-1 osteosarcoma-bearing mice with a combination of apomine and lovastatin significantly reduced tumor progression in these mice compared with single treatments, which had no effect at the doses used." | ( Brion, R; Ebetion, FH; Heymann, D; Moriceau, G; Redini, F; Roelofs, AJ; Rogers, MJ, 2012) |
| "Despite improvements in the treatment of osteosarcoma, there is a need for new therapeutic strategies, in particular for the treatment of recurrent tumors and metastases." | ( Li, Z; Peng, H; Xu, Q; Ye, Z, 2012) |
| "The response to IIF treatment of osteosarcoma SaOS-2, MG63, and U2OS cells and of bone marrow-derived MSC was the subject of investigation." | ( Donati, D; Dozza, B; Lucarelli, E; Orlandi, M; Papi, A; Pierini, M; Scotlandi, K; Tresca, G, 2012) |
| "Thirty-one treatment naive osteosarcoma patients evaluated prospectively by PET-CT scan preceding and after 3 cycles of NACT and surgery during 2006 to 2008." | ( Bajpai, J; Bakhshi, S; Gamnagatti, S; Khan, SA; Kumar, R; Malhotra, A; Rastogi, S; Safaya, R; Sharma, MC; Sreenivas, V, 2011) |
| "The potential to treat osteosarcoma by inhibition of Gli2 and the role of the pathway in ovarian fibromas and other connective tissue tumors is also discussed (Nagao et al." | ( Cain, JE; Healy, JM; Kelleher, FC; Thomas, DM; Watkins, DN, 2012) |
| "ILC is well tolerated in heavily treated osteosarcoma patients and did not appear to have the typical toxicities associated with intravenous cisplatin." | ( Bell, MD; Chou, AJ; Gorlick, R; Gupta, R; Meyers, PA; Riewe, KO, 2013) |
| "Information is scarce on systemic treatment of pelvic osteosarcoma because most chemotherapy protocols for osteosarcoma include patients with extremity tumors and aged up to 30-40 years." | ( Alberghini, M; Fabbri, N; Ferrari, C; Ferrari, S; Palmerini, E; Picci, P; Staals, E, 2012) |
| "Local control is the major issue in the treatment of pelvic osteosarcoma." | ( Alberghini, M; Fabbri, N; Ferrari, C; Ferrari, S; Palmerini, E; Picci, P; Staals, E, 2012) |
| "In this study, we treated osteosarcoma cell lines with 5-Aza-CdR, which is a widely-used DNA methyltransferase inhibitor, and found dose-dependent reduction in cell growth, conversion of cell morphology to a non-motile phenotype, and obvious increase in apoptosis." | ( Guo, QN; Huang, Y; Li, Y; Lv, Y; Meng, G, 2014) |
| "Intratumoral treatment of canine osteosarcoma and melanoma xenografts in mice resulted in inhibition of tumor growth and prolonged survival." | ( Alemany, R; Cascalló, M; Laborda, E; Moreno, R; Pastor, J; Puig-Saus, C; Rodriguez-García, A, 2014) |
| "Results showed that treatment of osteosarcoma cells with simvastatin at 3 to 10 µM doses decreases cell proliferation, migration, and invasion in a time- and dose-dependent manner." | ( Fernández-Pérez, L; García-Castellano, JM; Guerra, B; Hernández-Perera, O; Sánchez-Gómez, M; Sandoval-Usme, MC; Umaña-Pérez, A, 2014) |
| "Chemotherapy for treatment of osteosarcoma was demonstrated to be effective in eradicating primary tumor and pulmonary metastases in the mid-twentieth century." | ( Jaffe, N, 2014) |
| "A local cytotoxic therapy in the treatment of osteosarcoma and chondrosarcoma might improve the rate of metastasis and survival of patients." | ( Becker, M; Eckhard, L; Graf, C; Proschek, D; Rommens, PM; Theobald, M; Tonak, M; Wehler, TC, 2014) |
| "Individualized treatment of osteosarcoma may improve chemotherapy efficacy and the survival rate of osteosarcoma patients." | ( Chen, G; Fan, B; Fan, H; Fu, J; Gao, P; Guo, Z; Hu, Y; Huang, C; Li, J; Li, X; Shi, L; Wang, W; Wang, Z; Wu, S; Wu, Z; Xiao, X; Xu, C; Yu, X; Zhang, H; Zhu, H, 2015) |
| "When resistance to DOX treatment occurs, osteosarcoma may become not only resistant to the drug originally administered but also to a wide variety of structurally and mechanistically unrelated drugs." | ( Geng, YD; Guo, C; Kong, LY; Ni, K; Wang, ZD; Xia, YZ; Yang, L; Zhang, C, 2015) |
| "NsPEF has potential to treat osteosarcoma or bone metastasis." | ( Chen, X; Miao, X; Shao, Z; Yin, S; Zhang, Y, 2015) |
| "Doxorubicin plays a major role in the treatment of osteosarcoma disorders." | ( Chen, H; Fang, S; Guo, WC; Ji, P; Mei, HJ; Wang, XJ; Yang, J; Yu, L, 2014) |
| "While chondrosarcoma is mainly treated surgically, osteosarcoma therapy consists of both chemotherapy and surgical resection of the tumor." | ( Gosheger, G; Guder, WK; Hardes, J; Nottrott, M; Streitbürger, A, 2015) |
| "To provide novel strategies for future treatment of osteosarcoma, the properties of the scaffold, including its in vitro extended-release properties, the inhibition effects of ADM-PLGA-NHAC on the osteosarcoma MG63 cells, and its bone repair capacity, were investigated in vivo and in vitro." | ( Cai, BT; Cao, YL; Rong, ZJ; Wu, GF; Yang, LJ; Zhang, ZJ; Zhu, LX, 2016) |
| "To overcome radioresistance in the treatment of osteosarcoma, a primary malignant tumor of the bone, radiotherapy is generally combined with radiosensitizers." | ( Jung, WG; Kim, EH; Kim, MS; Koh, JS; Kong, CB; Lee, KH, 2016) |
| "Current therapies available for the treatment of human osteosarcoma, an aggressive bone tumor, are insufficient." | ( Chiang, TB; Shih, CH; Wang, WJ, 2017) |
| "Metformin treatment of osteosarcoma cells enhanced the effects of chemotherapy via suppression of N-cadherin." | ( Fang, W; Huang, ZW; Kang, Y; Lu, JC; Shen, JN; Song, GH; Tang, QL; Wang, J; Wang, YQ; Xu, HY; Yang, HL; Zhu, XJ; Zou, CY, 2017) |
| "High-dose methotrexate has been a treatment for osteosarcoma; however, its nephrotoxic effects are considerable." | ( Altaf, S; Broomall, E; Cooper, J; Hogan, MC; Khan, S; Rodriguez, V; Scott, K; Wyatt, KD, 2018) |
| "Furthermore, pretreatment of osteosarcoma cells with PD98059, an inhibitor of ERK1/2, inhibited honokiol-induced apoptosis and autophagy." | ( Chen, Y; Fang, X; Huang, K; Ma, Y; Shen, S; Wu, Y; Zhang, R, 2018) |
| "Chemoresistance during treatment of osteosarcoma (OS) is attracting more and more attention as the main clinical obstacle." | ( Chen, L; Fang, C; Yan, H; Zhang, B, 2018) |
| "Hence, an effective treatment for osteosarcoma has yet to be developed." | ( Cai, Z; Jewison, DE; Maran, A; Miller, AL; Okuno, SH; Shogren, KL; Waletzki, BE; Yaszemski, MJ; Zang, J; Zuo, D, 2018) |
| "Here we show that treatment of 143B osteosarcoma cells with decitabine (DAC, 5-Aza-2'-deoxycytidine) induces expression of ERα and leads to decreased proliferation and concurrent induction of osteoblast differentiation." | ( El Ayachi, I; Fatima, I; Garcia-Lopez, J; Khalid, AB; Krum, SA; Kumpati, J; Lillo Osuna, MA; Miranda-Carboni, GA; Seagroves, TN; Slayden, AV, 2019) |
| "Nowadays chemotherapy is the main treatment for osteosarcoma disease, even if limited by the lack of selectivity between healthy and cancer cells during the inhibition of cell division." | ( Ambrosio, L; Caporali, M; Fasolino, I; Peruzzini, M; Raucci, MG; Serrano-Ruiz, M; Soriente, A, 2019) |
| "The conventional treatment of osteosarcoma mainly consists of combining neoadjuvant chemotherapy with surgical approach." | ( Cheng, R; Cui, W; Dai, Y; Liu, H; Ni, Q; Wu, W; Ye, T, 2018) |
| "In this study, we found that DP treatment repressed osteosarcoma (OS) cell growth in a dose-dependent manner." | ( Fan, Y; Li, L; Liu, X; Wang, Z; Xie, J; Zhang, L, 2019) |
| "Current clinical treatments for osteosarcoma are limited by disease recurrence and primary or secondary chemoresistance." | ( Li, WY; Ma, K; Zhang, C, 2019) |
| "Herein, we propose a method by treating osteosarcoma cells and normal human osteoblasts with mannose as a stimulant, which greatly promotes the metabolic discrimination of osteosarcoma cells at the single-cell level." | ( Fang, Z; Ouyang, J; Wang, R; Yao, H; Zhang, X; Zhao, H, 2020) |
| "The application of radiotherapy (RT) to treat osteosarcoma (OS) has been limited, but this is starting to change as the ability to target radiation energy to niches improves." | ( Chen, MH; Chiang, CS; Hou, KT; Liu, TY; Tung, FI; Zheng, LJ, 2020) |
| "A mainstay of treatment in osteosarcoma is removal of the primary tumor." | ( Blank, B; Kallis, MP; Maloney, C; Soffer, SZ; Steinberg, BM; Symons, M, 2020) |
| "Currently, available treatment for osteosarcoma is combinational chemotherapy of doxorubicin, cisplatin, and methotrexate before and after surgery with overall 5-year survival rate of less than 40%." | ( Annamalai, V; Kotakonda, M; Periyannan, V, 2020) |
| "Investigations of alternative treatments for osteosarcoma, while promising, have led to multi-drug resistance." | ( Bose, S; Koski, C; Vu, AA, 2020) |
| "In this study, we found that DEX treating osteosarcoma cells inhibited cell viability, proliferation and adhesion, while it promoted cell apoptosis." | ( Chen, L; Cheng, J; Gao, J; Jin, S; Le, C; Li, N; Liu, H; Yan, R, 2021) |
| "This study developed a novel treatment for osteosarcoma by delivering ZOL to the target region locally and sustainably." | ( Aizawa, M; Honda, M; Kameda, Y; Sato, T, 2021) |
| "The efficacy of apatinib in the treatment of osteosarcoma is competitive with current evidence, and it is worth noting that its low cost can significantly improve patient compliance and increase therapeutic value." | ( Chen, X; Tan, X; Yao, H, 2021) |
| "Clinical treatment of Osteosarcoma (OS) encounters great challenges of postsurgical tumor recurrence and extensive bone defect." | ( Chen, Y; Lai, Y; Li, H; Li, L; Liu, B; Long, J; Qin, L; Teng, B; Wang, D; Yao, Z; Yu, XF; Zhang, W, 2021) |
| "Although the treatment of osteosarcoma has improved, the overall survival rate of this common type of osseous malignancies has not changed for four decades." | ( Dongdong, C; Hua, G; Kang, Q; Qingcheng, Y; Shijie, L; Zhen, P, 2021) |
| "Lay abstract Traditional treatment for osteosarcoma (bone cancer) includes drugs that cause cell damage, such as ifosfamide and etoposide." | ( Bautista, F; Campbell-Hewson, Q; Gaspar, N; Huang, J; Okpara, CE, 2021) |
| "It provides an alternative for the treatment of osteosarcoma in the future." | ( Du, H; Jiang, S; Wang, Q; Zhang, W, 2022) |
| "In our search for new approaches to treat osteosarcoma, we previously detected multiple chaperone proteins in the surface-exposed proteome of canine osteosarcoma cells." | ( Bracha, S; Goodall, CP; Ishmael, JE; Mattos, DR; McPhail, KL; Milovancev, M; Serrill, JD; Wan, X; Weinman, MA, 2022) |
| "The combination treatment of osteosarcoma by localized, sustained co-delivery of DOX and CDDP by PLGA-PEG-PLGA hydrogel may serve as a promising strategy for efficient clinical treatment of osteosarcoma." | ( Cong, M; Hou, Y; Ma, H; Si, M; Wang, D; Xia, Y, 2022) |
| "All medical files of patients treated for osteosarcoma in a single pediatric haemato-oncology center between November 2011 and August 2021 were retrospectively reviewed." | ( Elhasid, R; Levin, D; Manisterski, M; Peled, Y; Shiran, S; Shukrun, R, 2022) |
| "Despite tremendous advances in treating osteosarcoma (OS), the survival rates of patients have failed to improve dramatically over the past decades." | ( Bo, Z; Gan, F; Hu, Y; Jiang, M; Jike, Y; Li, J; Liu, K; Qin, W; Xie, M, 2022) |
| "These analyses may be beneficial to the treatment of osteosarcoma in the future." | ( Chu, D; Jiang, J; Lai, X; Liu, L; Tao, J, 2022) |
| "These analyses may be beneficial to the treatment of osteosarcoma in the future." | ( Chu, D; Jiang, J; Lai, X; Liu, L; Tao, J, 2022) |
| "These analyses may be beneficial to the treatment of osteosarcoma in the future." | ( Chu, D; Jiang, J; Lai, X; Liu, L; Tao, J, 2022) |
| "Resistance to doxorubicin treatment in osteosarcoma cells was correlated with inflammation in the microenvironment, and signal transducer and activator of transcription 3 (STAT3) inhibition diminished the inflammation-related differences in drug resistance but ultimately did not improve the efficacy of doxorubicin." | ( Bashor, CJ; Chim, LK; Mikos, AG; Williams, IL, 2023) |
| "How to effectively treat malignant osteosarcoma remains clinically challenging." | ( Gao, M; Li, L; Lin, S; Ma, C; Wang, Y; Wu, Y; Zhang, LW; Zhang, S, 2023) |
| "Further, PEITC-treated osteosarcoma cells experienced a sudden increase in ATP level, and later its content was decreased." | ( Li, J; Liu, J; Lv, H; Lyu, Y; Xie, L; Zhen, C, 2023) |
| "Clinical treatment of osteosarcoma encounters great challenges of postsurgical tumor recurrence and extensive bone defect." | ( Chen, L; Dai, H; Liu, W; Liu, Z; Luo, Z; Mu, C; Wang, J; Xia, Y; Xu, C; Zhuang, P, 2023) |
| "Curcuma has been used as an adjuvant treatment for osteosarcoma (OS) due to its anticancer compounds." | ( Dong, H; Feng, Y; Hu, M; Huang, F; Jiang, Z; Li, H; Ma, L; Ren, Y; Sun, W; Yan, H; Zeng, W, 2023) |
| "In this study, we treated osteosarcoma cells with an HSP90 inhibitor, 17-demethoxygeldanamycin hydrochloride (17-DMAG), and assessed the changes in the MET signaling pathway and also the antitumor effect of the drug." | ( Itonaga, I; Iwasaki, T; Kawano, M; Kubota, Y; Tanaka, K; Tsumura, H, 2023) |
| "The surgical treatment of osteosarcoma results in significant bone defects and risks of tumor recurrence." | ( Fan, D; Heng, C; Hui, J; Ma, X; Zheng, X, 2024) |